Patient ID Sex Race Diagnosis Age Tumor Stage Tumor grade Disease Status Relapse Type Survival Status Survival Time Smoking history Drinking history Prior Malignancy Diabetes History Chronic Pancreatitis History Family History of Cancer Missense Mutation - KRAS Missense Mutation - TP53 Missense Mutation - CDKN2A Missense Mutation - SMAD4 Subtype - Moffitt Subtype - Collisson Subtype - Bailey Subtype - PacPaint hidden hidden hidden
TCGA-2J-AAB1 Male White Mucinous adenocarcinoma 65 IIB G3 Complete response NA Deceased 66 Moderate smoker Weekly Drinker No No No No G12D,G12R R175H No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-2J-AAB4 Male White Adenocarcinoma, NOS 48 IIB G2 Complete response NA Alive 729 NA NA No No Yes NA G12V Y126N No No Classical Classical Progenitor Classical 2 G12 Yes
TCGA-2J-AAB6 Male White PDAC 75 IIA G2 Disease progression Distant recurrence/metastasis Deceased 293 NA NA No No No NA G12V R273H No No Basal Quasi-mesenchymal Squamous Basal 1 G12 Yes
TCGA-2J-AAB8 Male White PDAC 71 IIB G3 Unknown NA Alive 80 NA NA No No No NA G12R No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-2J-AAB9 Female White PDAC 70 IIB G1 Complete response Distant recurrence/metastasis Deceased 627 NA Weekly Drinker No No No Yes G12D No No No Basal Exocrine ADEX Classical 2 G12 No
TCGA-2J-AABA Male White PDAC 55 IIB G2 Disease progression Distant recurrence/metastasis Deceased 607 Heavy smoker NA No No Yes NA No No No No Classical Classical Progenitor NA 2 No No
TCGA-2J-AABE Male White PDAC 73 IIA G2 Complete response NA Alive 663 Light smoker Weekly Drinker No Yes No No G12R No No No Basal Classical Progenitor Classical 2 G12 No
TCGA-2J-AABF Male White PDAC 73 IIB G3 Disease progression Distant recurrence/metastasis Deceased 691 Light smoker Weekly Drinker No No No Yes G12D No No No Classical Exocrine Progenitor Classical 2 G12 No
TCGA-2J-AABH Male White Adenocarcinoma, NOS 61 IIA G3 Complete response Distant recurrence/metastasis Alive 1287 NA NA No No No Yes G12V,G12S No No No Classical Exocrine Progenitor Classical 4 G12 No
TCGA-2J-AABI Female White Adenocarcinoma, NOS 55 IIA G3 Disease progression Distant recurrence/metastasis Alive 788 Heavy smoker Social/Occasional drinker No No Yes No G12R No No No Basal Quasi-mesenchymal Squamous Basal 3 G12 No
TCGA-2J-AABK Male White PDAC 71 IIB G2 Complete response NA Alive 440 NA NA No No No NA G12V V272A No No Classical Exocrine Progenitor Classical 2 G12 Yes
TCGA-2J-AABO Male White PDAC 43 IIB G2 Disease progression Local recurrence and distant metastasis Alive 440 Light smoker NA No No No Yes G12V G266V No No Basal Exocrine ADEX Classical 2 G12 Yes
TCGA-2J-AABP Female White Carcinoma, NOS 58 IIB G4 Complete response NA Alive 355 NA Weekly Drinker No No No Yes No G245D No No NA NA NA NA 1 No Yes
TCGA-2J-AABR Female White PDAC 60 IIA G3 Disease progression Distant recurrence/metastasis Alive 412 NA NA Yes No No NA G12V C141Y No No Basal Exocrine ADEX Basal 2 G12 Yes
TCGA-2J-AABT Female White PDAC 72 IIB G2 Unknown NA Alive 319 NA Social/Occasional drinker Yes Yes Yes No G12R No No No Classical Classical Immunogenic Classical 1 G12 No
TCGA-2J-AABU Male White PDAC 56 IIB G3 Disease progression Distant recurrence/metastasis Deceased 277 NA Daily Drinker No No No No No No No No Basal Quasi-mesenchymal Squamous Basal 1 No No
TCGA-2J-AABV Male White PDAC 74 IIB G4 Disease progression Distant recurrence/metastasis Deceased 652 Moderate smoker NA No No No NA G12V R282W No No Classical Exocrine ADEX Classical 2 G12 Yes
TCGA-2L-AAQA Male White PDAC 76 IIB G2 Disease progression NA Deceased 143 Moderate smoker None No No No NA G12V R175H No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-2L-AAQE Male White PDAC 56 IIB G2 Disease progression NA Deceased 684 Moderate smoker Daily Drinker No Yes Yes NA G12D No H83Y No Basal Classical Squamous Classical 2 G12 No
TCGA-2L-AAQI Male White PDAC 66 IIB G3 Disease progression NA Deceased 103 NA None No NA Yes No G12V R283P No No Basal Exocrine Progenitor Classical 1 G12 Yes
TCGA-2L-AAQJ Female White PDAC 49 III G2 Disease progression NA Deceased 394 NA None No No No NA G12D G266E No No Classical Classical Progenitor Classical 2 G12 Yes
TCGA-2L-AAQL Male White PDAC 82 IIB G3 Disease progression NA Deceased 292 NA Daily Drinker No No No No Q61R No No No Classical Exocrine Progenitor Classical 1 Q61 No
TCGA-2L-AAQM Male White PNET 52 IIB G1 Stable disease NA Alive 914 NA Daily Drinker No NA No NA No No No No NA NA NA NA 3 No No
TCGA-3A-A9I5 Male White PDAC 57 TXN0MX G1 Complete response NA Alive 1612 NA NA Yes No No Yes No No No No Classical Exocrine ADEX Classical 5 No No
TCGA-3A-A9I7 Male Black/African-American PDAC 45 IIB G2 Unknown Local recurrence Alive 1309 NA NA No No No No G12D No H83Y No Classical Exocrine Immunogenic Classical 4 G12 No
TCGA-3A-A9I9 Male White PDAC 67 IIA G2 Stable disease Local recurrence Deceased 634 Heavy smoker Weekly Drinker No No No Yes G12R G245S No No Classical Exocrine ADEX Classical 2 G12 Yes
TCGA-3A-A9IB Female White PDAC 69 IIB G3 NA NA Deceased 224 Light smoker NA No Yes Yes No G12D Y220C No No Basal Quasi-mesenchymal Squamous Basal 1 G12 Yes
TCGA-3A-A9IC Female White PDAC 61 IIB G2 Stable disease NA Deceased 738 NA Weekly Drinker No No Yes Yes G12R No No No Classical Quasi-mesenchymal Squamous Classical 3 G12 No
TCGA-3A-A9IH Female White PDAC 66 IA G2 Stable disease Distant recurrence/metastasis Alive 874 Smoker, NOS Daily Drinker No No Yes No G12R V143E No A96D Basal Classical Progenitor Basal 3 G12 Yes
TCGA-3A-A9IJ Male White PNET 65 IB G1 Complete response NA Alive 1854 Moderate smoker NA Yes No No No No No No No NA NA NA NA 6 No No
TCGA-3A-A9IL Female White PNET 39 I G1 NA NA Alive 2558 NA NA Yes No No No No No No No NA NA NA NA 8 No No
TCGA-3A-A9IN Female White PNET 62 IB G2 Complete response NA Alive 2084 NA Daily Drinker No No No Yes No No No No NA NA NA NA 6 No No
TCGA-3A-A9IO Male White PNET 55 TXNXMX G1 NA NA Alive 1436 NA Social/Occasional drinker No Yes No No No No No No NA NA NA NA 4 No No
TCGA-3A-A9IR Female White PNET 64 IB G1 Complete response NA Alive 1164 Smoker, NOS Social/Occasional drinker No No No Yes No No No No NA NA NA NA 4 No No
TCGA-3A-A9IS Male White PNET 67 IB G1 Complete response NA Alive 932 NA NA No No No No No No No No NA NA NA NA 3 No No
TCGA-3A-A9IU Male White PDAC 65 IIB G3 Unknown Distant recurrence/metastasis Deceased 458 NA Social/Occasional drinker No No No No G12D P72A,A70T No No Basal Exocrine Squamous Basal 2 G12 Yes
TCGA-3A-A9IV Female White PNET 59 IB G1 Complete response NA Alive 967 NA Social/Occasional drinker No No No Yes No No No No NA NA NA NA 3 No No
TCGA-3A-A9IX Male White PDAC 40 IA G2 Complete response NA Alive 901 Light smoker Social/Occasional drinker No Yes No No G12D No No R361C Basal Exocrine ADEX Classical 3 G12 No
TCGA-3A-A9IZ Male White PDAC 47 IIB G2 Disease progression Local recurrence Deceased 308 NA NA No No No No G12D S241Y No No Basal Classical Squamous Classical 1 G12 Yes
TCGA-3A-A9J0 Male White PDAC 75 IIB G2 Disease progression Distant recurrence/metastasis Alive 377 NA NA No No No No No No No No Classical Classical Progenitor Classical 2 No No
TCGA-3E-AAAY Male White PDAC 67 IIB G3 Unknown Distant recurrence/metastasis Alive 2172 NA None No No No NA G12D No No No Classical Exocrine ADEX Classical 6 G12 No
TCGA-3E-AAAZ Male White PDAC 71 IIA G2 Unknown New Primary Tumor Deceased 2182 NA NA No NA NA NA G12V No No D351A Classical Exocrine Progenitor Classical 6 G12 No
TCGA-F2-6879 Male White Adenocarcinoma, NOS 57 IIB G2 Complete response Distant recurrence/metastasis Deceased 334 Smoker, NOS Daily Drinker No No No Yes G12V Y220C No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-F2-6880 Male White PDAC 70 IIB G1 Complete response NA Alive 295 Light smoker Daily Drinker No Yes No No No No No No NA NA NA NA 1 No No
TCGA-F2-7273 Male Black/African-American PDAC 54 IIB G3 Disease progression Distant recurrence/metastasis Alive 360 NA NA No No No No No No No No NA NA NA NA 1 No No
TCGA-F2-7276 Male White PDAC 64 IIB G1 Disease progression NA Deceased 216 NA NA No Yes No Yes No No No No NA NA NA NA 1 No No
TCGA-F2-A44G Female White PDAC 79 IIB G2 Complete response Local recurrence Alive 214 NA Daily Drinker Yes No No No G12D No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-F2-A44H Male White PDAC 65 IIA G2 Unknown NA Alive 158 NA NA No Yes No Yes No No No No Classical Exocrine ADEX Classical 1 No No
TCGA-F2-A7TX Male White PDAC 77 IIB G3 Disease progression NA Deceased 95 Smoker, NOS Daily Drinker No Yes No Yes G12D V197M No No Basal Exocrine ADEX Basal 1 G12 Yes
TCGA-F2-A8YN Male White PDAC 76 IIA G2 Disease progression NA Alive 167 Heavy smoker Social/Occasional drinker No Yes No Yes G12R No No No Basal Classical Progenitor Classical 1 G12 No
TCGA-FB-A4P5 Female White PDAC 69 IIB G2 NA NA Alive 4 Moderate smoker NA No No No Yes No No No No Basal Exocrine ADEX Classical 1 No No
TCGA-FB-A4P6 Male White PDAC 54 IIB G1 NA Local recurrence Alive 620 Moderate smoker None No No No No No No No No Classical Exocrine ADEX Classical 2 No No
TCGA-FB-A545 Female White PDAC 72 IIB G2 NA Distant recurrence/metastasis Alive 378 NA NA No No NA Yes G12V R273C No No Basal Quasi-mesenchymal Squamous Basal 2 G12 Yes
TCGA-FB-A5VM Male White PDAC 74 IB G3 NA Distant recurrence/metastasis Alive 177 Moderate smoker Social/Occasional drinker No Yes No No Q61H No No No Basal Quasi-mesenchymal Squamous Basal 1 Q61 No
TCGA-FB-A78T Female White PDAC 71 IIB G2 NA NA Alive 1 Light smoker NA No No NA Yes G13C,G12A R248L No No Classical Exocrine Progenitor Classical 1 G12|G13 Yes
TCGA-FB-A7DR Male Asian Mucinous adenocarcinoma 48 IIA G2 NA NA Alive 166 Light smoker Weekly Drinker No No NA No G12V No No No NA NA NA NA 1 G12 No
TCGA-FB-AAPP Male White PDAC 71 IIB G3 Disease progression Distant recurrence/metastasis Deceased 485 Smoker, NOS Social/Occasional drinker No No No Yes No No No No NA NA NA NA 2 No No
TCGA-FB-AAPQ Male White PDAC 65 IIB G2 NA NA Deceased 1130 Moderate smoker NA No Yes No NA G12D No No R361H Classical Classical Progenitor NA 4 G12 No
TCGA-FB-AAPS Female White PDAC 62 IIB G2 Unknown NA Alive 228 Light smoker NA No No No NA G12D H179Y No No Basal Exocrine Immunogenic NA 1 G12 Yes
TCGA-FB-AAPU Female Asian PDAC 41 IIA G2 Disease progression NA Deceased 381 NA None No No Yes NA G12R No No No Classical Classical Progenitor NA 2 G12 No
TCGA-FB-AAPY Male White PDAC 71 IIB G2 Complete response NA Deceased 1059 Moderate smoker Social/Occasional drinker No Yes NA Yes G12D No No No Classical Exocrine Progenitor NA 3 G12 No
TCGA-FB-AAPZ Male White PDAC 54 IIB G3 Complete response Distant recurrence/metastasis Alive 716 NA NA No No No Yes G12R No No No Basal Exocrine Squamous NA 2 G12 No
TCGA-FB-AAQ0 Male White PDAC 68 IIA G3 Complete response NA Deceased 473 NA NA No Yes No Yes G12R Y205S No No Classical Classical Progenitor NA 2 G12 Yes
TCGA-FB-AAQ1 Male White PDAC 49 IIB G2 Stable disease NA Deceased 123 Smoker, NOS NA No No No NA G12D No No No Basal Exocrine ADEX NA 1 G12 No
TCGA-FB-AAQ2 Female White PDAC 81 IIB G3 Partial response Distant recurrence/metastasis Deceased 153 NA None No Yes No No G12D P278S No No Basal Quasi-mesenchymal Squamous NA 1 G12 Yes
TCGA-FB-AAQ3 Female White PDAC 65 IIB G2 Complete response NA Deceased 31 NA None No No No Yes G12D No No No Classical Exocrine Progenitor NA 1 G12 No
TCGA-FB-AAQ6 Male White PDAC 85 IA G2 Disease progression Local recurrence Deceased 244 Smoker, NOS None Yes No No NA G12V R248Q No G352V Classical Classical Progenitor NA 1 G12 Yes
TCGA-FZ-5919 Female White PDAC 59 IIB G3 Disease progression Distant recurrence/metastasis Deceased 741 NA NA No No NA Yes G12D V173L No No NA NA NA NA 3 G12 Yes
TCGA-FZ-5920 Male Black/African-American PDAC 52 IIB G3 NA NA Deceased 61 NA NA No NA NA NA G12D No No No NA NA NA NA 1 G12 No
TCGA-FZ-5921 Female NA PDAC 85 IIB GX Disease progression Local recurrence Deceased 155 NA NA No NA NA NA G12V P152L No No NA NA NA NA 1 G12 Yes
TCGA-FZ-5922 Male White PDAC 81 IIA G2 Disease progression Local recurrence Deceased 1101 NA NA No No No NA G12V No No No NA NA NA NA 4 G12 No
TCGA-FZ-5923 Male White PDAC 71 IV G1 Disease progression NA Deceased 619 NA NA No NA NA Yes G12D No No No NA NA NA NA 2 G12 No
TCGA-FZ-5924 Male White PDAC 83 IIA G3 Disease progression NA Deceased 480 NA NA Yes NA NA NA G12R R248Q No No NA NA NA NA 2 G12 Yes
TCGA-FZ-5926 Female White PDAC 73 III G2 Disease progression NA Deceased 541 NA NA No NA NA NA G12D No No No NA NA NA NA 2 G12 No
TCGA-H6-8124 Female White PDAC 56 IIB G3 Unknown Distant recurrence/metastasis Alive 259 Light smoker Social/Occasional drinker No No No Yes G12V C238Y No No Basal Quasi-mesenchymal Squamous NA 1 G12 Yes
TCGA-H6-A45N Female White Adenocarcinoma, NOS 88 IIB G3 NA Local recurrence Alive 363 Never smoker Daily Drinker Yes No No Yes G12V R282G No No Classical Exocrine ADEX Classical 1 G12 Yes
TCGA-H8-A6C1 Male White Adenocarcinoma, NOS 53 IIA G2 Discrepancy Distant recurrence/metastasis Alive 455 Moderate smoker Social/Occasional drinker No No No Yes G12V No No No NA NA NA NA 2 G12 No
TCGA-HV-A5A3 Male Asian PDAC 50 IIA G2 Complete response NA Deceased 128 Smoker, NOS Social/Occasional drinker No No No NA G12D R248W No No Basal Classical Squamous Basal 1 G12 Yes
TCGA-HV-A5A4 Female Asian PDAC 72 IIA G2 Complete response NA Alive 232 NA NA No No No NA G12V No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-HV-A5A5 Female Asian PDAC 61 IIB G2 Complete response NA Alive 289 NA NA No No No NA G12D Y205F No No Classical Exocrine ADEX NA 1 G12 Yes
TCGA-HV-A5A6 Female Asian PDAC 65 IIB G1 Complete response Distant recurrence/metastasis Alive 1953 NA NA No No No NA G12D No No No Classical Classical Squamous Classical 6 G12 No
TCGA-HV-A7OL Male Asian PDAC 70 IIA G2 Stable disease Distant recurrence/metastasis Alive 252 NA Daily Drinker No Yes No NA G12D N131I No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-HV-A7OP Male Asian PDAC 72 IIB GX Discrepancy Distant recurrence/metastasis Alive 859 NA Weekly Drinker No No No No G12D No No No NA NA NA NA 3 G12 No
TCGA-HV-AA8V Male Asian PDAC 50 IIB G3 Discrepancy Distant recurrence/metastasis Alive 910 Heavy smoker Weekly Drinker No No No NA G12V P151R No A118V Basal Classical Squamous Classical 3 G12 Yes
TCGA-HV-AA8X Female Asian PDAC 75 IIB G2 Discrepancy Distant recurrence/metastasis Deceased 532 NA NA No No No NA G12D D259V No No Classical Classical Progenitor Classical 2 G12 Yes
TCGA-HZ-7289 Male White Adenocarcinoma, NOS 77 IIB G1 NA Distant recurrence/metastasis Alive 240 NA NA Yes NA NA NA No No No No NA NA NA NA 1 No No
TCGA-HZ-7918 Male White PDAC 72 IIB G3 NA Distant recurrence/metastasis Alive 542 NA NA No NA NA NA No No No No NA NA NA NA 2 No No
TCGA-HZ-7919 Female White PDAC 52 IIB G2 NA NA Alive 20 NA NA No NA NA NA G12R No No D537H Classical Classical Progenitor Classical 1 G12 No
TCGA-HZ-7920 Male White PDAC 71 IB G2 NA NA Alive 0 NA NA No NA NA NA No No No No NA NA NA NA 0 No No
TCGA-HZ-7922 Female White PDAC 61 IIB G1 NA NA Alive 4 NA NA No NA NA NA Q61H No No No Classical Exocrine ADEX Classical 1 Q61 No
TCGA-HZ-7923 Male White PDAC 65 IIA G2 NA NA Alive 8 NA NA No NA NA NA No No No No NA NA NA NA 1 No No
TCGA-HZ-7924 Female White PDAC 60 IIA G2 NA Distant recurrence/metastasis Alive 831 NA NA No NA NA NA No No No No NA NA NA NA 3 No No
TCGA-HZ-7925 Male White PDAC 66 IIB G2 NA Local recurrence Alive 364 NA NA No NA NA NA G12V No No No Basal Quasi-mesenchymal Immunogenic Classical 1 G12 No
TCGA-HZ-7926 Male Black/African-American PDAC 57 IIB G1 NA Distant recurrence/metastasis Alive 340 NA NA No NA NA NA G12D No No No Classical Exocrine Progenitor NA 1 G12 No
TCGA-HZ-8001 Male White PDAC 69 III G2 NA NA Alive 19 NA NA No NA NA NA G12V R248Q No No Basal Quasi-mesenchymal Immunogenic Basal 1 G12 Yes
TCGA-HZ-8002 Male White PDAC 61 IIB G2 NA NA Alive 24 NA NA No NA NA NA G12D No No No Basal Exocrine ADEX Classical 1 G12 No
TCGA-HZ-8003 Female White PDAC 65 IIB G2 NA Distant recurrence/metastasis Alive 21 NA NA No NA NA NA G12R No No No Classical Exocrine ADEX Classical 1 G12 No
TCGA-HZ-8005 Male White PDAC 81 IIB G3 Disease progression NA Deceased 120 NA NA No NA NA NA Q61H No No No Basal Quasi-mesenchymal Squamous Basal 1 Q61 No
TCGA-HZ-8315 Female White PDAC 54 IIA G2 NA NA Alive 28 NA NA No NA NA NA G12D H179R No No Basal Exocrine ADEX Classical 1 G12 Yes
TCGA-HZ-8317 Female White PDAC 69 IIB G1 NA NA Alive 16 NA NA No NA NA NA No No No H382L Classical Exocrine ADEX Classical 1 No No
TCGA-HZ-8519 Male White Adenocarcinoma, NOS 73 IA G3 NA NA Alive 3 NA NA No NA NA NA No No No No Classical Exocrine Immunogenic Classical 1 No No
TCGA-HZ-8636 Female White PDAC 58 IV G3 NA NA Alive 5 NA NA No NA NA NA G12V No No No Classical Quasi-mesenchymal Immunogenic Classical 1 G12 No
TCGA-HZ-8637 Female White PDAC 76 IIB G3 NA NA Alive 0 NA NA No NA NA NA G12V G245S No No Classical Quasi-mesenchymal Immunogenic Classical 0 G12 Yes
TCGA-HZ-8638 Female White Mucinous adenocarcinoma 84 IA GX NA NA Alive 91 NA NA No NA NA NA No No No No NA NA NA NA 1 No No
TCGA-HZ-A49G Female White PDAC 58 IIB G2 NA NA Alive 23 NA NA No NA NA NA G12D C275F E119K No Classical Exocrine ADEX Classical 1 G12 Yes
TCGA-HZ-A49H Female White PDAC 68 IIB G2 NA NA Alive 29 NA NA No NA NA NA G12V No No No Classical Exocrine ADEX Classical 1 G12 No
TCGA-HZ-A49I Male White PDAC 77 IIB G2 NA NA Alive 0 NA NA No NA NA NA G12D M246R No No Classical Classical Progenitor Classical 0 G12 Yes
TCGA-HZ-A4BH Male White PDAC 75 IIB G3 NA NA Alive 194 NA NA No NA NA NA G12D C135Y H83D No Basal Classical Immunogenic Classical 1 G12 Yes
TCGA-HZ-A4BK Male White Adenocarcinoma, NOS 72 IIB G3 NA NA Alive 46 NA NA Yes NA NA NA G12D P151T No No Classical Exocrine Progenitor Classical 1 G12 Yes
TCGA-HZ-A77O Female White PDAC 77 IIB G2 NA Local recurrence Alive 98 NA NA No No No No G12V S127F H83Y No Basal Exocrine ADEX Basal 1 G12 Yes
TCGA-HZ-A77P Male White Adenocarcinoma, NOS 77 IIB G1 NA NA Alive 13 NA NA No No No Yes G12V No No No Classical Exocrine ADEX Classical 1 G12 No
TCGA-HZ-A77Q Female White Adenocarcinoma, NOS 55 IIB G2 NA NA Alive 33 Light smoker NA Yes Yes No No G12R R248W No No Basal Quasi-mesenchymal Immunogenic Classical 1 G12 Yes
TCGA-HZ-A8P0 Male White PDAC 76 IIB G1 NA NA Alive 0 Light smoker Social/Occasional drinker Yes No No Yes Q61H No No No Classical Exocrine ADEX Classical 0 Q61 No
TCGA-HZ-A8P1 Male White PDAC 81 IB G1 NA NA Alive 7 Light smoker NA No No No No G12D No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-HZ-A9TJ Male White Adenocarcinoma, NOS 70 IV G2 Unknown Distant recurrence/metastasis Alive 603 NA NA No NA NA NA G12V R175H No No Classical Classical Progenitor Classical 2 G12 Yes
TCGA-IB-7644 Female White PDAC 65 IV G2 Disease progression Distant recurrence/metastasis Alive 347 Moderate smoker Social/Occasional drinker No Yes No No G12V R110L No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-IB-7645 Female NA PDAC 44 IIB G1 Disease progression Distant recurrence/metastasis Deceased 1502 NA NA No No No No G12V No No No Classical Quasi-mesenchymal Immunogenic Classical 5 G12 No
TCGA-IB-7646 Male White PDAC 60 IIB G2 Disease progression Local recurrence Deceased 145 NA Social/Occasional drinker No No No No G12D I255T No No Basal Quasi-mesenchymal Squamous Basal 1 G12 Yes
TCGA-IB-7647 Male White PDAC 41 IIB G2 Disease progression Distant recurrence/metastasis Deceased 666 NA Social/Occasional drinker No No No Yes G12V R248W No No Classical Classical Immunogenic Classical 2 G12 Yes
TCGA-IB-7649 Female NA PDAC 73 IIB G2 Partial response Distant recurrence/metastasis Deceased 467 Heavy smoker NA No No No NA Q61H No No No Classical Exocrine ADEX Classical 2 Q61 No
TCGA-IB-7651 Female White PDAC 64 IIB G2 Complete response Local recurrence Deceased 603 Light smoker Weekly Drinker No Yes No Yes G12D No No R496H Classical Exocrine Immunogenic Classical 2 G12 No
TCGA-IB-7652 Female Asian PDAC 49 IIB G2 Complete response NA Alive 476 NA None No No No No G12R R175H No No Classical Exocrine ADEX Classical 2 G12 Yes
TCGA-IB-7654 Male White PDAC 80 IIB G2 Disease progression NA Deceased 476 NA NA Yes No No NA G12R R282W No No NA NA NA NA 2 G12 Yes
TCGA-IB-7885 Female White PDAC 78 IIB G2 Complete response NA Alive 851 Light smoker None No No No Yes G12V No No No Basal Quasi-mesenchymal Squamous Classical 3 G12 No
TCGA-IB-7886 Male White PDAC 80 IIB G3 Complete response NA Deceased 123 Moderate smoker Daily Drinker No No No No G12C No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-IB-7887 Female White PDAC 62 IIB G2 NA NA Deceased 110 Light smoker NA No No No Yes G12R S215G No No Basal Classical Progenitor Classical 1 G12 Yes
TCGA-IB-7888 Female Black/African-American PDAC 66 IIA G2 Stable disease Distant recurrence/metastasis Deceased 1332 NA NA No No No NA No No No No Classical Classical Immunogenic Classical 4 No No
TCGA-IB-7889 Female White PDAC 85 IIB G1 Disease progression Local recurrence Deceased 481 NA NA No No No Yes G12V No No R361C Basal Exocrine ADEX Classical 2 G12 No
TCGA-IB-7890 Male NA PDAC 73 IB G3 Disease progression Distant recurrence/metastasis Deceased 598 NA Social/Occasional drinker No No No NA Q61R No No No Basal Quasi-mesenchymal Squamous Basal 2 Q61 No
TCGA-IB-7891 Female White PDAC 49 IIB G1 Complete response Distant recurrence/metastasis Alive 872 Moderate smoker Social/Occasional drinker No No No Yes No G245V No L109Q Classical Exocrine ADEX Classical 3 No Yes
TCGA-IB-7893 Male White PDAC 64 IIA G3 Disease progression Distant recurrence/metastasis Deceased 117 Smoker, NOS Social/Occasional drinker No Yes No Yes G12D I254S No No Basal Quasi-mesenchymal Squamous Basal 1 G12 Yes
TCGA-IB-7897 Female White PDAC 53 IIB G2 Disease progression Local recurrence and distant metastasis Deceased 486 Smoker, NOS Social/Occasional drinker No No No Yes No No No No Basal Quasi-mesenchymal Immunogenic Classical 2 No No
TCGA-IB-8126 Female White PDAC 79 III G1 NA Distant recurrence/metastasis Alive 83 Light smoker None No Yes No Yes No No No No Classical Exocrine ADEX Classical 1 No No
TCGA-IB-8127 Male White PDAC 59 IIB G2 Complete response Local recurrence and distant metastasis Alive 486 Moderate smoker NA No No No No G12D R273C No No Basal Exocrine Squamous Classical 2 G12 Yes
TCGA-IB-A5SO Male White PDAC 71 IIB G2 Disease progression Local recurrence Alive 329 NA NA No No No No G12D No No No Classical Classical Immunogenic Classical 1 G12 No
TCGA-IB-A5SP Male White PDAC 77 IIA G2 Unknown Local recurrence Alive 300 NA None No No No Yes G12D S241F No No Classical Classical Progenitor Classical 1 G12 Yes
TCGA-IB-A5SQ Female White PDAC 56 IB G2 Complete response Distant recurrence/metastasis Deceased 219 NA Social/Occasional drinker No No No Yes No No No No Basal Quasi-mesenchymal Immunogenic Basal 1 No No
TCGA-IB-A5SS Female White PDAC 64 IIB G3 Complete response Distant recurrence/metastasis Deceased 460 Light smoker NA Yes Yes No NA G12D R282W No No Basal Quasi-mesenchymal Squamous Basal 2 G12 Yes
TCGA-IB-A5ST Female White PDAC 64 IIB G2 Complete response NA Alive 8 NA NA No No No Yes No R248W No No Classical Quasi-mesenchymal Immunogenic Classical 1 No Yes
TCGA-IB-A6UF Male White PDAC 63 IIB G2 Unknown Distant recurrence/metastasis Alive 593 Moderate smoker Daily Drinker No Yes No NA G12R R273H No No Basal Exocrine Squamous Basal 2 G12 Yes
TCGA-IB-A6UG Male White PDAC 65 IIB G3 Partial response Distant recurrence/metastasis Deceased 230 Moderate smoker None No No No NA G12D R248W No No Basal Exocrine ADEX Basal 1 G12 Yes
TCGA-IB-A7LX Male White PDAC 57 IIB G2 Disease progression Distant recurrence/metastasis Deceased 250 NA Social/Occasional drinker No No No NA G12D No No No Basal Quasi-mesenchymal Squamous Basal 1 G12 No
TCGA-IB-A7M4 Male White PDAC 81 IIB G3 Complete response NA Alive 181 Heavy smoker Daily Drinker No No No Yes G12D P250L No No Basal Classical Squamous Basal 1 G12 Yes
TCGA-IB-AAUM Male White PDAC 76 IIB G3 Partial response NA Alive 8 NA None No Yes No NA G12D No No W509G Classical Exocrine ADEX Classical 1 G12 No
TCGA-IB-AAUN Female White PDAC 74 IB G2 Complete response Local recurrence Deceased 144 NA None No No No Yes G12D R337C No No Basal Exocrine ADEX Basal 1 G12 Yes
TCGA-IB-AAUO Female White PDAC 64 IIB G3 Partial response Distant recurrence/metastasis Deceased 239 NA Social/Occasional drinker No No No No G12D No No No Basal Quasi-mesenchymal Squamous Basal 1 G12 No
TCGA-IB-AAUP Male White PDAC 68 IIB G2 Unknown NA Alive 290 Smoker, NOS None No Yes No Yes G12D No No No Classical Quasi-mesenchymal Immunogenic Classical 1 G12 No
TCGA-IB-AAUQ Male White PDAC 50 IIB G2 Partial response Distant recurrence/metastasis Deceased 183 Heavy smoker Social/Occasional drinker No No No Yes G12D H179Y No No Basal Quasi-mesenchymal Squamous Basal 1 G12 Yes
TCGA-IB-AAUR Male White PDAC 67 IIB G1 Partial response Local recurrence and distant metastasis Alive 330 Smoker, NOS None No Yes No NA G12R No No D355G Basal Quasi-mesenchymal Immunogenic Classical 1 G12 No
TCGA-IB-AAUS Female White PDAC 84 IIB G2 Unknown NA Alive 179 Moderate smoker Daily Drinker No Yes No Yes No No No No Basal Exocrine Immunogenic Classical 1 No No
TCGA-IB-AAUT Male White Mucinous adenocarcinoma 65 IIB G1 Unknown NA Alive 188 Light smoker None No Yes No Yes No No No No Classical Exocrine ADEX Classical 1 No No
TCGA-IB-AAUU Male White PDAC 35 IIB G3 Unknown NA Alive 153 Light smoker None No No No Yes G12R No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-IB-AAUV Male White PDAC 49 IIB G2 Unknown NA Alive 229 Heavy smoker None No No No No No No No No NA NA NA NA 1 No No
TCGA-IB-AAUW Female White PDAC 63 IIB G3 Unknown Local recurrence Alive 185 NA Social/Occasional drinker No Yes No Yes No No No No NA NA NA NA 1 No No
TCGA-L1-A7W4 Female White PDAC 48 IIB G3 Disease progression Distant recurrence/metastasis Alive 164 NA None No No No No No No No No NA NA NA NA 1 No No
TCGA-LB-A7SX Female Black/African-American PDAC 74 IIB G2 Stable disease NA Alive 127 Moderate smoker Daily Drinker Yes No Yes Yes No No No No Basal Classical Progenitor Classical 1 No No
TCGA-LB-A8F3 Female Black/African-American PDAC 64 IIA G1 NA NA Alive 35 NA None No No NA Yes No No No No Classical Exocrine ADEX Classical 1 No No
TCGA-LB-A9Q5 Female White PDAC 63 IIB G3 Unknown Local recurrence Alive 290 Never smoker None No No No Yes G12D No No G384D Basal Exocrine ADEX Classical 1 G12 No
TCGA-M8-A5N4 Female NA PDAC 48 IIA G2 Partial response Local recurrence Alive 584 NA Social/Occasional drinker No No No NA G12D V274F No No Basal Classical Progenitor Classical 2 G12 Yes
TCGA-OE-A75W Male White PDAC 75 IIA G1 Unknown Distant recurrence/metastasis Alive 146 Moderate smoker Daily Drinker No Yes Yes Yes G12D No H83Y No Classical Classical Progenitor Classical 1 G12 No
TCGA-PZ-A5RE Female White PDAC 44 IIB G3 Unknown Distant recurrence/metastasis Alive 393 NA NA No NA NA NA Q61H L194H No L536P Classical Classical Progenitor Classical 2 Q61 Yes
TCGA-Q3-A5QY Male White PDAC 58 IIB G2 Unknown NA Alive 105 NA NA No Yes No No No No No No Basal Quasi-mesenchymal Immunogenic Basal 1 No No
TCGA-Q3-AA2A Female White PDAC 64 IB G1 NA NA Alive 94 NA None No No NA NA G12V No No No Classical Classical Progenitor Classical 1 G12 No
TCGA-RB-A7B8 Female White Adenocarcinoma, NOS 81 IIB G2 Complete response Local recurrence Alive 449 NA None No No No Yes G12R No No No Classical Classical Progenitor Classical 2 G12 No
TCGA-RB-AA9M Male White PDAC 43 IIB G3 Disease progression Distant recurrence/metastasis Alive 258 NA None No No No Yes G12V No G23C No Basal Classical Immunogenic Classical 1 G12 No
TCGA-RL-AAAS Female White PDAC 60 IB G2 Complete response NA Alive 9 NA NA No Yes No No No No No No NA NA NA NA 1 No No
TCGA-S4-A8RM Male White PDAC 67 IIB G3 Complete response NA Alive 397 Moderate smoker Weekly Drinker No Yes No Yes G12V No No No Classical Classical Progenitor Classical 2 G12 No
TCGA-S4-A8RO Female White PDAC 75 IIB G2 Complete response Distant recurrence/metastasis Alive 291 NA Weekly Drinker Yes No No No G12D R282W No No Basal Classical Squamous Basal 1 G12 Yes
TCGA-S4-A8RP Female White PDAC 77 IIB G3 Unknown NA Deceased 702 Moderate smoker Social/Occasional drinker No No No Yes G12R No No No Classical Exocrine Progenitor Classical 2 G12 No
TCGA-US-A774 Female White PDAC 76 IIB G3 Disease progression Distant recurrence/metastasis Deceased 695 Light smoker Social/Occasional drinker No No No Yes G12D No No No Classical Exocrine ADEX Classical 2 G12 No
TCGA-US-A776 Male White Mucinous adenocarcinoma 61 IIA G2 NA NA Alive 844 NA None No Yes No No No No No No Classical Classical Progenitor NA 3 No No
TCGA-US-A779 Female White PDAC 54 IIB G1 NA NA Deceased 511 NA Social/Occasional drinker No No No No G12D No No No Classical Classical Progenitor Classical 2 G12 No
TCGA-US-A77E Male White Adenocarcinoma, NOS 73 IIB G3 NA Distant recurrence/metastasis Deceased 430 Smoker, NOS Daily Drinker Yes No No Yes No No No No Classical Classical Progenitor Classical 2 No No
TCGA-US-A77G Male White PDAC 64 IIB G2 NA NA Deceased 12 NA Daily Drinker No No No NA G12R No No No Classical Exocrine Progenitor Classical 1 G12 No
TCGA-US-A77J Female White PDAC 81 IIB G2 NA NA Deceased 568 NA Daily Drinker No No No Yes No No No No NA NA NA NA 2 No No
TCGA-XD-AAUG Female White PDAC 66 IV G2 Discrepancy NA Alive 161 NA Weekly Drinker No NA NA Yes G12V G154V No No Classical Exocrine Immunogenic Classical 1 G12 Yes
TCGA-XD-AAUH Female White PDAC 57 IIB G2 Unknown New Primary Tumor Alive 164 NA Daily Drinker No No No Yes No No No No Basal Quasi-mesenchymal Immunogenic Classical 1 No No
TCGA-XD-AAUI Female White PDAC 50 IIB G2 Disease progression Distant recurrence/metastasis Alive 202 Smoker, NOS Social/Occasional drinker No Yes NA No G12V R248Q No No Basal Exocrine Immunogenic Classical 1 G12 Yes
TCGA-XD-AAUL Male White PDAC 56 IIA G2 Unknown NA Alive 188 Moderate smoker None Yes No Yes No G12R H179R No No Basal Classical Squamous Classical 1 G12 Yes
TCGA-XN-A8T3 Male White PDAC 67 IB G2 Disease progression Distant recurrence/metastasis Alive 951 Smoker, NOS NA No No No NA G12D R273C No No Basal Exocrine ADEX Basal 3 G12 Yes
TCGA-XN-A8T5 Female White PDAC 53 IB G2 Disease progression Distant recurrence/metastasis Alive 720 Light smoker NA No Yes No NA G12R No No No Basal Quasi-mesenchymal Immunogenic Classical 2 G12 No
TCGA-YB-A89D Male White PDAC 59 IIB G2 Unknown NA Alive 160 NA NA No Yes No Yes G12R No No R361C Classical Classical Progenitor Classical 1 G12 No
TCGA-YH-A8SY Female White Adenocarcinoma, NOS 73 T3N1MX G2 Unknown NA Alive 388 NA Weekly Drinker No No No No G12V R175H No No Basal Quasi-mesenchymal Squamous NA 2 G12 Yes
TCGA-YY-A8LH Female White PDAC 61 IIB G3 Complete response NA Alive 1834 Heavy smoker Social/Occasional drinker No No No Yes G12V No No No Classical Classical Progenitor Classical 6 G12 No
TCGA-Z5-AAPL Female White PDAC 74 IIA G1 Complete response NA Alive 21 NA NA No NA NA NA No N239D No No Classical Quasi-mesenchymal Immunogenic Classical 1 No Yes
Overview
Help
Patient Statistics
Help
Sex
Survival Status
Age at Diagnosis
Race
Tumour Statistics
Help
Tumor Stage
Tumor Grade
Missense Mutation - KRAS
Missense Mutation - TP53
Molecular Subtype - Moffitt
Molecular Subtype - Bailey
Molecular Subtype - Collisson
Molecular Subtype - PacPaint
Cohort Summary
Variant Identification
Oncoplot help
LolliPlot help
Loading...
Somatic Interactions help
Survival Analysis help
Loading...
Drug Prediction
Cancer Genome Interpreter (CGI) help
CGI Biomarker CGI Bioactivity
Gene Protein Alteration Alteration Match Drug Effect Tumour Evidence
SF3B1 K666N Complete Match Spliceosome inhibitor Responsive CANCER Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R), KRAS MUT (G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R), KRAS MUT (G12D Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R), KRAS MUT (G12D Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12R), KRAS MUT (G12D Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12R), KRAS MUT (G12D Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12R), KRAS MUT (G12D Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12R), KRAS MUT (G12D Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12R), KRAS MUT (G12D Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12R), KRAS MUT (G12D Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match FAS inhibitor Responsive L Case report
KRAS G12R), KRAS MUT (G12D Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12R), KRAS MUT (G12D Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12R), KRAS MUT (G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R), KRAS MUT (G12D Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12R), KRAS MUT (G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12R), KRAS MUT (G12D Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12R), KRAS MUT (G12D Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 R175H Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R175H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R175H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R175H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R175H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R175H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R175H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R175H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R175H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R175H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R175H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R175H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12V Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12V Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12V Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12V Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12V Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12V Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12V Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12V Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12V Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12V Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12V Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12V Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12V Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12V Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12V Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12V Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12V Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12V Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12V Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12V Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12V Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12V Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match FAS inhibitor Responsive L Case report
KRAS G12V Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12V Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12V Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12V Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12V Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12V Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12V Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 Y126N Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y126N Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y126N Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y126N Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y126N Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y126N Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y126N Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y126N Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y126N Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y126N Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y126N Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y126N Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y126N Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273H Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R273H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R273H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R273H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R273H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R273H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R273H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R273H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R273H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R273H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ALK R1212H Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK R1212H Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK R1212H Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK R1212H Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R1212H Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK R1212H Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK R1212H Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK R1212H Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK R1212H Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK R1212H Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK R1212H Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK R1212H Different Alteration ALK inhibitor Responsive COREAD Case report
ALK R1212H Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK R1212H Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
KRAS G12R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12R Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12R Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12R Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12R Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12R Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12R Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12R Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12R Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12R Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12R Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12R Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12R Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12R Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12R Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12R Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12R Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12R Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12R Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12R Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12R Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12R Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match FAS inhibitor Responsive L Case report
KRAS G12R Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12R Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12R Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12R Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12R Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12R Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12R Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 S166* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S166* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S166* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S166* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S166* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S166* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S166* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S166* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S166* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S166* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S166* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S166* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S166* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S166* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S166* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12D Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12D Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12D Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12D Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12D Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12D Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12D Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12D Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12D Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12D Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12D Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12D Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12D Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12D Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12D Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12D Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12D Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12D Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12D Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12D Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12D Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12D Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match FAS inhibitor Responsive L Case report
KRAS G12D Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12D Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12D Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12D Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12D Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12D Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12D Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12D Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12D Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 Q104* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q104* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q104* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q104* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q104* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q104* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q104* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q104* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q104* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q104* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q104* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q104* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q104* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ARID1A E1542* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A E1542* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A E1542* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A E1542* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
AKT3 V190A Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
RNF43 Q22* Complete Match Porcupine inhibitor Responsive COREAD Case report
TP53 C242* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C242* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C242* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C242* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C242* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C242* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C242* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C242* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C242* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C242* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C242* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C242* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C242* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C242* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C242* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A R80* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R80* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R80* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A R80* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A R80* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R80* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R80* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A R80* Different Alteration CDK4/6 inhibitor Responsive CM Case report
KRAS G12S), KRAS MUT (G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12S), KRAS MUT (G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12S), KRAS MUT (G12V Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12S), KRAS MUT (G12V Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12S), KRAS MUT (G12V Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12S), KRAS MUT (G12V Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12S), KRAS MUT (G12V Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12S), KRAS MUT (G12V Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12S), KRAS MUT (G12V Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12S), KRAS MUT (G12V Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match FAS inhibitor Responsive L Case report
KRAS G12S), KRAS MUT (G12V Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12S), KRAS MUT (G12V Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12S), KRAS MUT (G12V Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12S), KRAS MUT (G12V Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12S), KRAS MUT (G12V Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12S), KRAS MUT (G12V Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12S), KRAS MUT (G12V Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 V272A Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V272A Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V272A Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V272A Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V272A Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V272A Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V272A Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V272A Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V272A Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V272A Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V272A Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V272A Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V272A Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V272A Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V272A Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BRAF R462T Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUAD Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive HISEC, HISLC, NSCLC NCCN guidelines
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive CM NCCN guidelines
BRAF R462T Different Mutation Vemurafenib;Cobimetinib (BRAF inhibitor;MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Trametinib (MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Pan-RAF inhibitor Responsive CANCER Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Resistant CANCER Pre-clinical
BRAF R462T Different Mutation ERK inhibitor Responsive HNSC, BT Case report
BRAF R462T Different Mutation EGFR TK inhibitor Resistant LUAD Case report
BRAF R462T Different Mutation MEK inhibitor Responsive CM Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive CM Early trials
BRAF R462T Different Mutation BRAF inhibitor Responsive CM Case report
BRAF R462T Different Mutation Sorafenib (Pan-TK inhibitor) Responsive CM Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) No Responsive COREAD Early trials
BRAF R462T Different Mutation MEK inhibitor (BRAF inhibitor;MEK inhibitor;anti-EGFR mAb inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Irinotecan;Vemurafenib;Cetuximab (TOPO1 inhibitor;BRAF inhibitor;EGFR mAb inhibitor) Responsive COREAD NCCN guidelines
BRAF R462T Different Mutation Panitumumab;Dabrafenib;BYL719 (EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation BRAF inhibitor;anti-EGFR mAb inhibitor +/- PI3K pathway inhibitor Responsive COREAD Early trials
BRAF R462T Different Mutation BRAF inhibitor;EGFR mAb inhibitor +/- PI3K inhibitor Responsive COREAD Early trials
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive MA Early trials
BRAF R462T Different Mutation BRAF inhibitor;MEK inhibitor Responsive TH Early trials
BRAF R462T Different Mutation BRAF inhibitor;HSP90 inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Panitumumab (EGFR mAb inhibitor) Resistant COREAD Late trials
BRAF R462T Different Mutation Panitumumab;Dabrafenib;Trametinib (EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor) Responsive COREAD Early trials
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive LUAD FDA guidelines
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive NSCLC NCCN guidelines
BRAF R462T Different Mutation MEK inhibitor Responsive TH Early trials
BRAF R462T Different Mutation BRAF inhibitor;PI3K pathway inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive LUAD, TH Early trials
BRAF R462T Different Mutation MEK inhibitor Responsive OV Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive HCL, LUAD, MYMA Case report
BRAF R462T Different Mutation Pan-RAF inhibitor Responsive CM Early trials
BRAF R462T Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
BRAF R462T Different Mutation BRAF inhibitor Responsive G Pre-clinical
BRAF R462T Different Mutation BRAF inhibitor;CDK2/4 inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation PLX4720 (BRAF inhibitor) Responsive MA Pre-clinical
BRAF R462T Different Mutation Vemurafenib (BRAF inhibitor) Responsive THCA Early trials
BRAF R462T Different Mutation Selumetinib (MEK inhibitor) Responsive PG Early trials
BRAF R462T Different Mutation ERK inhibitor Responsive LUAD Early trials
BRAF R462T Different Mutation ERK inhibitor Responsive CM Pre-clinical
BRAF R462T Different Mutation Dabrafenib;Trametinib (BRAF inhibitor;MEK inhibitor) Responsive NEU Case report
BRAF R462T Different Mutation BRAF inhibitor Responsive OV Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive GIST Case report
BRAF R462T Different Mutation Dabrafenib (BRAF inhibitor) Responsive CM FDA guidelines
BRAF R462T Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUAD Case report
BRAF R462T Different Alteration Sorafenib (Pan-TK inhibitor) Responsive CM, LUAD, PRAD Pre-clinical
BRAF R462T Different Alteration MEK inhibitor Responsive LUAD, CM, PRAD Pre-clinical
BRAF R462T Different Alteration Selumetinib (MEK inhibitor) Responsive OV Case report
BRAF R462T Different Alteration BRAF inhibitor;MEK inhibitor Responsive LUAD Case report
TP53 G266V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G266V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G266V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G266V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G266V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G266V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G266V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G266V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G266V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G266V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G266V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245D Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245D Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245D Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245D Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245D Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245D Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245D Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245D Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245D Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245D Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245D Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245D Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245D Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245D Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245D Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C141Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C141Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C141Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C141Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C141Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C141Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C141Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C141Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C141Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C141Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C141Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C141Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C141Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C141Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C141Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282W Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R282W Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R282W Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R282W Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R282W Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R282W Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282W Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282W Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282W Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R282W Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R282W Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R282W Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282W Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R282W Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282W Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA P539R Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA P539R Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA P539R Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA P539R Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA P539R Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA P539R Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA P539R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA P539R Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
TP53 Q38* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q38* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q38* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q38* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q38* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q38* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q38* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q38* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q38* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q38* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q38* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q38* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q38* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A H83Y Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A H83Y Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A H83Y Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A H83Y Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A H83Y Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A H83Y Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A H83Y Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A H83Y Different Alteration CDK4/6 inhibitor Responsive CM Case report
TP53 R283P Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R283P Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R283P Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R283P Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R283P Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R283P Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R283P Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R283P Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R283P Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R283P Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R283P Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R283P Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R283P Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R283P Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R283P Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G266E Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G266E Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G266E Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G266E Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G266E Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G266E Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G266E Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266E Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G266E Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G266E Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G266E Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G266E Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266E Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G266E Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G266E Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KRAS Q61R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61R Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61R Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS Q61R Different Mutation MEK inhibitor Responsive ALL Pre-clinical
KRAS Q61R Different Mutation Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS Q61R Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS Q61R Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS Q61R Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61R Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS Q61R Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS Q61R Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS Q61R Complete Match BET inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS Q61R Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS Q61R Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS Q61R Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS Q61R Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS Q61R Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS Q61R Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS Q61R Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61R Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS Q61R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61R Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS Q61R Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS Q61R Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS Q61R Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match FAS inhibitor Responsive L Case report
KRAS Q61R Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS Q61R Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS Q61R Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS Q61R Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS Q61R Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61R Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS Q61R Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS Q61R Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS Q61R Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 splice_acceptor_variant Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 splice_acceptor_variant Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 splice_acceptor_variant Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 splice_acceptor_variant Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 splice_acceptor_variant Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 splice_acceptor_variant Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 splice_acceptor_variant Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 splice_acceptor_variant Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 splice_acceptor_variant Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 splice_acceptor_variant Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_acceptor_variant Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 splice_acceptor_variant Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_acceptor_variant Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y220C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y220C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y220C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y220C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y220C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y220C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y220C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y220C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y220C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y220C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y220C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y220C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y220C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V143E Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V143E Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V143E Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V143E Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V143E Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V143E Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V143E Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V143E Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V143E Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V143E Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V143E Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V143E Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V143E Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V143E Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V143E Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A E120* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E120* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E120* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A E120* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A E120* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E120* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E120* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A E120* Different Alteration CDK4/6 inhibitor Responsive CM Case report
NTRK1 G357S Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 G357S Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 G357S Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 G357S Different Alteration Pan-TK inhibitor Responsive COREAD Case report
TP53 S241Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S241Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S241Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S241Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S241Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S241Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S241Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S241Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S241Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S241Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S241Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KMT2A L2896I Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A L2896I Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A L2896I Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A L2896I Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A L2896I Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A L2896I Different Alteration DOT1L inhibitor Responsive AML Early trials
NOTCH1 V453I Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 V453I Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 splice_donor_variant Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 splice_donor_variant Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 splice_donor_variant Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 splice_donor_variant Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 splice_donor_variant Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 splice_donor_variant Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 splice_donor_variant Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 splice_donor_variant Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 splice_donor_variant Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 splice_donor_variant Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 splice_donor_variant Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 splice_donor_variant Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CTNNB1 S45P Different Mutation Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) Responsive ED Early trials
CTNNB1 S45P Complete Match Tankyrase inhibitor Resistant COREAD Pre-clinical
TP53 E294* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E294* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E294* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E294* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E294* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E294* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E294* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E294* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E294* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E294* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E294* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E294* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E294* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E294* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E294* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RNF43 R145* Complete Match Porcupine inhibitor Responsive COREAD Case report
ARID1A R1276*), ARID1A MUT (splice_donor_variant Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A R1276*), ARID1A MUT (splice_donor_variant Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A R1276*), ARID1A MUT (splice_donor_variant Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A R1276*), ARID1A MUT (splice_donor_variant Complete Match ATR inhibitor Responsive CANCER Pre-clinical
TP53 V197M Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V197M Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V197M Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V197M Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V197M Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V197M Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V197M Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V197M Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V197M Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V197M Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V197M Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V197M Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V197M Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V197M Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V197M Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ZNRF3 Q411* Complete Match Porcupine inhibitor Responsive COREAD Pre-clinical
TP53 R273C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R273C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R273C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R273C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R273C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R273C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R273C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R273C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R273C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R273C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R273C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R273C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R273C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK3 M567T Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 M567T Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 M567T Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
KRAS Q61H Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61H Different Mutation Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS Q61H Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS Q61H Different Mutation MEK inhibitor Responsive ALL Pre-clinical
KRAS Q61H Different Mutation Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS Q61H Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS Q61H Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS Q61H Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61H Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS Q61H Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS Q61H Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS Q61H Complete Match BET inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS Q61H Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS Q61H Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS Q61H Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS Q61H Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS Q61H Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS Q61H Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS Q61H Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61H Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS Q61H Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS Q61H Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS Q61H Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS Q61H Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS Q61H Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match FAS inhibitor Responsive L Case report
KRAS Q61H Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS Q61H Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS Q61H Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS Q61H Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS Q61H Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS Q61H Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS Q61H Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS Q61H Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS Q61H Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
KRAS G12A), KRAS MUT (G13C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12A), KRAS MUT (G13C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12A), KRAS MUT (G13C Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12A Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12A Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12A), KRAS MUT (G13C Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12A), KRAS MUT (G13C Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12A), KRAS MUT (G13C Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12A), KRAS MUT (G13C Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12A), KRAS MUT (G13C Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12A), KRAS MUT (G13C Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12A), KRAS MUT (G13C Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12A), KRAS MUT (G13C Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match FAS inhibitor Responsive L Case report
KRAS G12A), KRAS MUT (G13C Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12A), KRAS MUT (G13C Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12A), KRAS MUT (G13C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12A), KRAS MUT (G13C Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12A), KRAS MUT (G13C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12A), KRAS MUT (G13C Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12A), KRAS MUT (G13C Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 R248L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK1 I491I Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 I491I Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 I491I Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 I491I Different Alteration Pan-TK inhibitor Responsive COREAD Case report
ESR1 S576S Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
GNAS R201C Complete Match JAK inhibitor Responsive CANCER Pre-clinical
TP53 H179Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 H179Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 H179Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 H179Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 H179Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 H179Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H179Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 H179Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 H179Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 H179Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 H179Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R213* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R213* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R213* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R213* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R213* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R213* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R213* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R213* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R213* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R213* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R213* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R213* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R213* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R213* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R213* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y205S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y205S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y205S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y205S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y205S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y205S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y205S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y205S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y205S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P278S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P278S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P278S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P278S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P278S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P278S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P278S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P278S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P278S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P278S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P278S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
JAK2 K385K Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
TP53 R248Q Complete Match HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248Q Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248Q Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248Q Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248Q Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248Q Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248Q Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248Q Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248Q Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248Q Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248Q Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248Q Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248Q Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA G118D Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA G118D Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA G118D Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA G118D Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA G118D Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA G118D Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA G118D Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA G118D Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
TP53 V173L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V173L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V173L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V173L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V173L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V173L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V173L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V173L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V173L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V173L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V173L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V173L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V173L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V173L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V173L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATR E1765* Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATR E1765* Complete Match Olaparib (PARP inhibitor) Responsive CANCER, OV Pre-clinical
ATR E1765* Different Alteration Olaparib (PARP inhibitor) Responsive OV, CANCER Pre-clinical
LRP1B R3064* Complete Match Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
LRP1B R3064* Different Alteration Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
TP53 P152L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P152L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P152L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P152L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P152L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P152L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P152L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P152L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P152L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P152L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P152L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P152L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P152L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P152L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P152L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BAP1 splice_acceptor_variant Complete Match EZH2 inhibitor Responsive MESO Pre-clinical
BAP1 splice_acceptor_variant Complete Match PARP inhibitor Responsive R, CANCER Pre-clinical
BAP1 splice_acceptor_variant Complete Match HDAC inhibitor Responsive CM Pre-clinical
BAP1 splice_acceptor_variant Different Alteration PARP inhibitor Responsive CANCER, R Pre-clinical
BAP1 splice_acceptor_variant Different Alteration EZH2 inhibitor Responsive MESO Pre-clinical
BAP1 splice_acceptor_variant Different Alteration HDAC inhibitor Responsive CM Pre-clinical
ATM splice_acceptor_variant Different Mutation AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM splice_acceptor_variant Complete Match Cisplatin (Chemotherapy) Responsive BLCA Early trials
ATM splice_acceptor_variant Complete Match Olaparib (PARP inhibitor) Responsive ST, PRAD Early trials
ATM splice_acceptor_variant Complete Match PARP inhibitor Responsive ST Early trials
ATM splice_acceptor_variant Complete Match ATR inhibitor Responsive COREAD Case report
ATM splice_acceptor_variant Complete Match DNA-PKc inhibitor Responsive LY Pre-clinical
ATM splice_acceptor_variant Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATM splice_acceptor_variant Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
ATM splice_acceptor_variant Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
ATM splice_acceptor_variant Different Alteration DNA-PKc inhibitor Responsive LY Pre-clinical
ATM splice_acceptor_variant Different Alteration PARP inhibitor Responsive ST Early trials
ATM splice_acceptor_variant Different Alteration ATR inhibitor Responsive COREAD Case report
ATM splice_acceptor_variant Different Alteration Cisplatin (Chemotherapy) Responsive BLCA Early trials
TP53 C238Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C238Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C238Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C238Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C238Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C238Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C238Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C238Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C238Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C238Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C238Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C238Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C238Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282G Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R282G Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R282G Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R282G Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R282G Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R282G Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R282G Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282G Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R282G Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R282G Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R282G Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R282G Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282G Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R282G Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R282G Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248W Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R248W Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R248W Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R248W Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R248W Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R248W Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R248W Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R248W Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R248W Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R248W Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R248W Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R248W Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Y205F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Y205F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Y205F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Y205F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Y205F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Y205F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Y205F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Y205F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Y205F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Y205F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Y205F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BCR R447H Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR R447H Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR R447H Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR R447H Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR R447H Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR R447H Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
TP53 N131I Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 N131I Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 N131I Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 N131I Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 N131I Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 N131I Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 N131I Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N131I Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N131I Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 N131I Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 N131I Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 N131I Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N131I Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 N131I Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N131I Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RNF43 splice_donor_variant Complete Match Porcupine inhibitor Responsive COREAD Case report
APC R499* Complete Match Tankyrase inhibitor Responsive COREAD Pre-clinical
TP53 P151R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P151R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P151R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P151R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P151R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P151R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P151R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P151R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P151R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P151R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 D259V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 D259V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 D259V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 D259V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 D259V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 D259V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 D259V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D259V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 D259V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 D259V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 D259V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 D259V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D259V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 D259V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 D259V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
KMT2A P3059L Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A P3059L Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A P3059L Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A P3059L Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A P3059L Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A P3059L Different Alteration DOT1L inhibitor Responsive AML Early trials
TP53 R196* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R196* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R196* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R196* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R196* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R196* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R196* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R196* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R196* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R196* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R196* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R196* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R196* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R196* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R196* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C135* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C135* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C135* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C135* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C135* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C135* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C135* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C135* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C135* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ERBB4 C213C Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ARID1A Q1947* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q1947* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q1947* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q1947* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
ERBB4 V299E Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
TP53 H179R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 H179R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 H179R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 H179R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 H179R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 H179R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 H179R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 H179R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 H179R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 H179R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 H179R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 H179R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 H179R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
GNAS R201H Complete Match JAK inhibitor Responsive CANCER Pre-clinical
TP53 C275F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C275F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C275F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C275F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C275F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C275F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C275F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C275F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C275F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C275F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C275F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C275F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C275F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C275F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C275F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 M246R Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 M246R Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 M246R Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 M246R Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 M246R Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 M246R Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 M246R Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 M246R Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 M246R Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 M246R Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 M246R Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 M246R Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 M246R Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 M246R Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 M246R Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135Y Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 C135Y Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 C135Y Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 C135Y Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 C135Y Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 C135Y Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 C135Y Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 C135Y Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 C135Y Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 C135Y Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135Y Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 C135Y Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 C135Y Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151T Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P151T Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P151T Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P151T Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P151T Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P151T Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P151T Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151T Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P151T Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P151T Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P151T Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P151T Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151T Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P151T Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P151T Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S127F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S127F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S127F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S127F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S127F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S127F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S127F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S127F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S127F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S127F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S127F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S127F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S127F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S127F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S127F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CDKN2A R58* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R58* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R58* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A R58* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A R58* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A R58* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A R58* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A R58* Different Alteration CDK4/6 inhibitor Responsive CM Case report
NRG1 intron_variant Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 intron_variant Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
PBRM1 splice_acceptor_variant Different Alteration Everolimus (MTOR inhibitor) Responsive R Pre-clinical
PBRM1 splice_acceptor_variant Complete Match anti-PD1 inhibitor Responsive RCCC Early trials
PBRM1 splice_acceptor_variant Complete Match Everolimus (MTOR inhibitor) Responsive RCC Early trials
PBRM1 splice_acceptor_variant Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
PBRM1 splice_acceptor_variant Different Alteration EZH2 inhibitor Responsive CANCER Pre-clinical
TP53 I255T Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 I255T Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 I255T Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 I255T Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 I255T Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 I255T Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 I255T Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 I255T Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 I255T Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 I255T Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 I255T Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I255T Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
BRD4 5-UTRSNV Different Alteration BET inhibitor Responsive NMC Case report
ESR1 R477L Different Alteration ESR1 inhibitor Resistant BRCA Pre-clinical
EPHA2 C369* Different Mutation MTOR inhibitor Responsive LUSC Pre-clinical
EPHA2 C369* Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUSC Pre-clinical
EPHA2 C369* Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive CANCER Pre-clinical
ERBB4 E1144* Different Mutation Lapatinib (ERBB2 inhibitor) Responsive CM Pre-clinical
ERBB4 E1144* Different Mutation ERBB2 inhibitor Resistant BRCA Case report
ERBB4 E1144*), ERBB4 MUT* (A672D Different Alteration Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) Responsive LUAD Pre-clinical
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive ST, BRCA, GEJA FDA guidelines
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration MK2206;Trastuzumab (allosteric AKT inhibitor;ERBB2 mAb inhibitor) Responsive SOLID Early trials
ERBB2 V842I Complete Match Lapatinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER, BRCA Pre-clinical
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive CANCER Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Case report
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Responsive BRCA, LUAD Case report
ERBB2 V842I Different Mutation Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive L Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Resistant BRCA Case report
ERBB2 V842I Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Case report
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive BRCA Pre-clinical
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Resistant BRCA Pre-clinical
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive CANCER Pre-clinical
ERBB2 V842I Complete Match Temsirolimus (MTOR inhibitor) Responsive LUAD Early trials
ERBB2 V842I Complete Match Dacomitinib (Pan ERBB inhibitor) Responsive NSCLC Early trials
ERBB2 V842I Complete Match Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation ERBB2 inhibitor Responsive LUAD Early trials
ERBB2 V842I Different Mutation Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation ERBB2 mAb inhibitor Responsive LUAD Early trials
ERBB2 V842I Different Mutation Neratinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation Lapatinib (ERBB2 inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Mutation Trastuzumab (ERBB2 mAb inhibitor) Responsive LUAD Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BRCA Late trials
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Responsive COREAD Late trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive OV Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive BLCA Case report
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor) Responsive COREAD Case report
ERBB2 V842I Different Alteration Rociletinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V842I Different Alteration Osimertinib (EGFR inhibitor) Resistant LUAD Case report
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration EGFR mAb inhibitor Resistant COREAD Early trials
ERBB2 V842I Different Alteration Lapatinib (ERBB2 inhibitor) Responsive BT Early trials
ERBB2 V842I Different Alteration Trastuzumab;HSP90 inhibitor (ERBB2 mAb inhibitor;HSP90 inhibitor) Responsive BRCA Early trials
ERBB2 V842I Different Alteration HER2 inhibitor;CDK4/6 inhibitor Responsive BRCA Pre-clinical
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Pertuzumab (ERBB2 mAb inhibitor) Responsive ST Early trials
ERBB2 V842I Different Alteration Trastuzumab;Everolimus;Chemotherapy (ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy) Responsive BRCA Early trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive ST, GEJA FDA guidelines
ERBB2 V842I Different Alteration ERBB2 inhibitor;CDK4/6 inhibitor Responsive BRCA Pre-clinical
ERBB2 V842I Different Alteration Ado-Trastuzumab Emtansine (EGFR mAb inhibitor) Responsive BRCA FDA guidelines
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) Responsive HNC Case report
ERBB2 V842I Different Alteration Neratinib (ERBB2 inhibitor) Responsive BRCA Late trials
ERBB2 V842I Different Alteration Trastuzumab (ERBB2 mAb inhibitor) No Responsive ED Early trials
ERBB2 V842I Different Alteration Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Responsive ED Pre-clinical
ERBB2 V842I Different Alteration Lapatinib;Chemotherapy (ERBB2 inhibitor;Chemotherapy) Responsive ST Early trials
ERBB2 V842I Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive ST Case report
ERBB2 V842I Different Alteration EGFR inhibitor Resistant LUAD Pre-clinical
EGFR D800G), EGFR MUT* (L683M), EGFR MUT* (R669* Different Alteration Erlotinib (EGFR inhibitor) Responsive L Case report
EGFR D800G), EGFR MUT* (L683M), EGFR MUT* (R669* Different Alteration Erlotinib (EGFR inhibitor) Responsive NSCLC Case report
ALK R200K Different Alteration ALK inhibitor;SRC inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive GB, LY Early trials
ALK R200K Different Alteration Lorlatinib (ALK&ROS1 inhibitor) Responsive NSCLC Early trials
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive THCA, IM Case report
ALK R200K Different Alteration HSP90 inhibitor Responsive LUAD Early trials
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive IM, COREAD Case report
ALK R200K Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD, NSCLC FDA guidelines
ALK R200K Different Alteration Brigatinib (Pan-TK inhibitor) Responsive NSCLC FDA guidelines
ALK R200K Different Alteration Entrictinib (Pan-TK inhibitor) Responsive COREAD Case report
ALK R200K Different Alteration Alectinib (ALK inhibitor) Responsive LUAD FDA guidelines
ALK R200K Different Alteration HSP90 inhibitor (HSP90 inhibitor) Responsive LUAD Early trials
ALK R200K Different Alteration ALK inhibitor;IGF1R inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration ALK inhibitor;MEK inhibitor Responsive LUAD Pre-clinical
ALK R200K Different Alteration novel ALK inhibitor Responsive LUAD Early trials
ALK R200K Different Alteration Ceritinib (ALK inhibitor) Responsive HEMATO Early trials
ALK R200K Different Alteration ALK inhibitor Responsive COREAD Case report
ALK R200K Different Alteration Alectinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ALK R200K Different Alteration MEK inhibitor (ALK inhibitor;MEK inhibitor) Responsive LUAD Pre-clinical
AKT3 5-UTRSNV Different Alteration ATP competitive AKT inhibitor Responsive BRCA Pre-clinical
ARID1A Q920* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q920* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q920* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q920* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
ABL1 3-UTRSNV), ABL1 MUT* (A1038V), ABL1 MUT* (R1009*), ABL1 MUT* (L599F), ABL1 MUT* (A487D), ABL1 MUT* (P131S Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
JAK2 S602I), JAK2 MUT* (R443* Different Alteration Ruxolitinib (JAK inhibitor) Responsive ALL Pre-clinical
SMARCA1 E1037* Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
SMARCA4 R978* Complete Match EZH2 inhibitor Responsive OVRT Case report
SMARCA4 R978* Complete Match AURKA inhibitor Responsive NSCLC Pre-clinical
SMARCA4 R978* Complete Match EZH2 inhibitor Responsive OV Case report
SMARCA4 R978* Different Alteration EZH2 inhibitor Responsive OVRT Case report
SMARCA4 R978* Different Alteration EZH2 inhibitor Responsive OV Case report
PDGFRA 3-UTRSNV), PDGFRA MUT* (A1014T), PDGFRA MUT* (D968N), PDGFRA MUT* (R522H Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive MDPS, MDS, ECL, HES FDA guidelines
PML H544Y Different Alteration Volasertib (PLK1 inhibitor) Responsive AML Early trials
PML H544Y Different Alteration Tretinoin (Retinoid) Responsive APML FDA guidelines
PML H544Y Different Alteration Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) Responsive AML FDA guidelines
FAT1 splice_acceptor_variant), FAT1 MUT (G3103* Complete Match BET inhibitor Responsive HNSC Pre-clinical
FANCA splice_acceptor_variant Complete Match Olaparib (PARP inhibitor) Responsive PRAD Case report
FANCA splice_acceptor_variant Different Alteration Olaparib (PARP inhibitor) Responsive PRAD Case report
FGFR3 V700A), FGFR3 MUT* (Q547Q Different Alteration FGFR inhibitor Responsive BLCA Case report
FGFR3 V700A), FGFR3 MUT* (Q547Q Different Alteration FGFR inhibitor Responsive G Early trials
FGFR3 V700A), FGFR3 MUT* (Q547Q Different Alteration FGFR inhibitor Responsive NSCLC Pre-clinical
DDR2 G505S Different Mutation Erlotinib (EGFR inhibitor) Responsive LUSC Case report
DDR2 G505S Different Mutation Dasatinib (BCR-ABL inhibitor) Responsive LUSC Case report
DDR2 G505S Complete Match Dasatinib (BCR-ABL inhibitor) Responsive LUSC Pre-clinical
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET P1070S), RET MUT* (R844W), RET MUT* (R770*), RET MUT* (A756D), RET MUT* (F329L), RET MUT* (R57W Different Alteration RET inhibitor Responsive TH Pre-clinical
RAF1 R618R Different Alteration Sorafenib (Pan-TK inhibitor) Responsive PRAD Pre-clinical
RAF1 R618R Different Alteration Pan-RAF inhibitor Responsive PRAD Pre-clinical
RAF1 R618R Different Alteration U0126 (MEK inhibitor) Responsive PRAD Pre-clinical
RAD51C splice_acceptor_variant Complete Match PARP inhibitor Responsive OV Early trials
ROS1 W21*), ROS1 MUT* (Y228Y), ROS1 MUT* (Q617H), ROS1 MUT* (V785M), ROS1 MUT* (K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive IM Case report
ROS1 W21*), ROS1 MUT* (Y228Y), ROS1 MUT* (Q617H), ROS1 MUT* (V785M), ROS1 MUT* (K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive NSCLC FDA guidelines
ROS1 W21*), ROS1 MUT* (Y228Y), ROS1 MUT* (Q617H), ROS1 MUT* (V785M), ROS1 MUT* (K2307N Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Case report
ROS1 W21*), ROS1 MUT* (Y228Y), ROS1 MUT* (Q617H), ROS1 MUT* (V785M), ROS1 MUT* (K2307N Different Alteration HSP90 inhibitor Responsive LUAD Pre-clinical
ROS1 W21*), ROS1 MUT* (Y228Y), ROS1 MUT* (Q617H), ROS1 MUT* (V785M), ROS1 MUT* (K2307N Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Early trials
MET P1078S), MET MUT* (L982M), MET MUT* (C818C), MET MUT* (H542H), MET MUT* (P295H), MET MUT* (M118L Different Alteration Crizotinib (ALK inhibitor) Responsive G Case report
MSH2 splice_acceptor_variant Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
MSH2 splice_acceptor_variant Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
MSH3 R734* Complete Match DNA-PKc inhibitor Responsive CANCER Pre-clinical
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A Q2575Q), MLL MUT* (D2298N), MLL MUT* (F1405F Different Alteration DOT1L inhibitor Responsive AML Early trials
NTRK3 P48P), NTRK3 MUT* (A435S), NTRK3 MUT* (intron_variant), NTRK3 MUT* (R645C), NTRK3 MUT* (R791W Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 P48P), NTRK3 MUT* (A435S), NTRK3 MUT* (intron_variant), NTRK3 MUT* (R645C), NTRK3 MUT* (R791W Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 P48P), NTRK3 MUT* (A435S), NTRK3 MUT* (intron_variant), NTRK3 MUT* (R645C), NTRK3 MUT* (R791W Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
NTRK1 T734M Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 T734M Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 T734M Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 T734M Different Alteration Pan-TK inhibitor Responsive COREAD Case report
NOTCH2 S613I), NOTCH2 MUT* (G1000G), NOTCH2 MUT* (A1599D), NOTCH2 MUT* (Q2389Q), NOTCH2 MUT* (3-UTRSNV Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
NOTCH1 D469Y), NOTCH1 MUT* (C833Y), NOTCH1 MUT* (A1707T), NOTCH1 MUT* (P1884P), NOTCH1 MUT* (A2101T Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 D469Y), NOTCH1 MUT* (C833Y), NOTCH1 MUT* (A1707T), NOTCH1 MUT* (P1884P), NOTCH1 MUT* (A2101T Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
NRG1 R220H), NRG1 MUT* (intron_variant), NRG1 MUT* (L77L Different Alteration Lapatinib (ERBB2 inhibitor) Responsive LUAD Pre-clinical
NRG1 R220H), NRG1 MUT* (intron_variant), NRG1 MUT* (L77L Different Alteration Afatinib (ERBB2 & EGFR inhibitor) Responsive LUAD Case report
BRD4 R10I), BRD4 MUT* (P327L), BRD4 MUT* (S662S), BRD4 MUT* (G691S), BRD4 MUT* (S717S), BRD4 MUT* (S1221S Different Alteration BET inhibitor Responsive NMC Case report
BCR intron_variant Different Alteration Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) Responsive CML, ALL FDA guidelines
BCR intron_variant Different Alteration Imatinib (BCR-ABL inhibitor & KIT inhibitor) Responsive ALL, CML FDA guidelines
BCR intron_variant Different Alteration Nilotinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant Different Alteration Bosutinib (BCR-ABL inhibitor) Responsive CML FDA guidelines
BCR intron_variant Different Alteration Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) Responsive ALL Pre-clinical
BCR intron_variant Different Alteration Dasatinib (BCR-ABL inhibitor) Responsive ALL, CML FDA guidelines
KRAS G12C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD FDA guidelines
KRAS G12C Different Mutation Cetuximab (EGFR mAb inhibitor) No Responsive COREAD Late trials
KRAS G12C Complete Match MEK inhibitor Responsive ALL Pre-clinical
KRAS G12C Complete Match Imatinib (BCR-ABL inhibitor & KIT inhibitor) Resistant GIST Case report
KRAS G12C Complete Match MEK inhibitor Responsive OV, CER, AML Pre-clinical
KRAS G12C Complete Match Abemaciclib (CDK4/6 inhibitor) Responsive L Early trials
KRAS G12C Complete Match MEK inhibitor;PI3K pathway inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12C Complete Match Sorafenib;MEK inhibitor (Pan-TK inhibitor;MEK inhibitor) Responsive HC Early trials
KRAS G12C Complete Match EGFR inhibitor Resistant L NCCN guidelines
KRAS G12C Complete Match CDK4 inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match Selumetinib (MEK inhibitor) Responsive NSCLC Early trials
KRAS G12C Complete Match BET inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match Decitabine;BCL2 inhibitor (Chemotherapy;BCL2 inhibitor) Responsive OV Pre-clinical
KRAS G12C Complete Match FAK inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match EGFR inhibitor Resistant NSCLC Pre-clinical
KRAS G12C Complete Match EZH2 inhibitor Resistant CANCER Pre-clinical
KRAS G12C Complete Match MEK inhibitor Responsive BT, L Early trials
KRAS G12C Complete Match MEK inhibitor;IGF1R inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match MTOR inhibitor;BH3 mimetics Responsive COREAD Pre-clinical
KRAS G12C Complete Match EGFR mAb inhibitor;MEK inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match pan-RAF inhibitor Responsive ED Case report
KRAS G12C Complete Match EGFR mAb inhibitor Resistant ST Pre-clinical
KRAS G12C Complete Match PI3K pathway inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12C Complete Match Selumetinib (MEK inhibitor) No Responsive L Early trials
KRAS G12C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive L Early trials
KRAS G12C Complete Match Trametinib;Ponatinib (MEK inhibitor;BCR-ABL inhibitor & Pan-TK inhibitor) Responsive LUAD Pre-clinical
KRAS G12C Complete Match Trastuzumab;Lapatinib (ERBB2 mAb inhibitor;ERBB2 inhibitor) Resistant COREAD Late trials
KRAS G12C Complete Match pan-RAF inhibitor Responsive L Early trials
KRAS G12C Complete Match JAK/TBK1/IKKε inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match FAS inhibitor Responsive L Case report
KRAS G12C Complete Match HSP90 inhibitor Responsive L Pre-clinical
KRAS G12C Complete Match ERK inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match PI3K pathway inhibitor;MEK inhibitor No Responsive PA Early trials
KRAS G12C Complete Match MEK inhibitor;BCL-XL inhibitor Responsive COREAD Pre-clinical
KRAS G12C Complete Match Gemcitabine;MEK inhibitor (Chemotherapy;MEK inhibitor) Responsive PA Early trials
KRAS G12C Complete Match Panitumumab (EGFR mAb inhibitor) Resistant COREAD NCCN guidelines
KRAS G12C Complete Match PI3K pathway inhibitor Resistant ED Pre-clinical
KRAS G12C Complete Match CDK4/6 inhibitor;MEK inhibitor Responsive CESC Pre-clinical
KRAS G12C Different Alteration BRAF inhibitor;MEK inhibitor Resistant COREAD Case report
KRAS G12C Different Alteration BRAF inhibitor;EGFR mAb inhibitor Resistant COREAD Case report
TP53 S215G Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S215G Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S215G Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S215G Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S215G Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S215G Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S215G Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S215G Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S215G Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S215G Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S215G Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S215G Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S215G Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S215G Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S215G Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q192* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 Q192* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 Q192* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 Q192* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 Q192* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 Q192* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 Q192* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 Q192* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 Q192* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 Q192* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q192* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 Q192* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 Q192* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
RET R57Q Different Alteration Nintedanib (Pan-TK inhibitor) Responsive LUAD Case report
RET R57Q Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration RET inhibitor Responsive LUAD Pre-clinical
RET R57Q Different Alteration Vandetanib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration Sunitinib (Pan-TK inhibitor) Responsive LUAD Early trials
RET R57Q Different Alteration Cabozantinib (Pan-kinase inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration Vandetanib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration Sunitinib (Pan-TK inhibitor) Responsive THCA Pre-clinical
RET R57Q Different Alteration RET inhibitor Responsive TH Pre-clinical
TP53 E298* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E298* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E298* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E298* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E298* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E298* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E298* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E298* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E298* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E298* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E298* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E298* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E298* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E298* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E298* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G199* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G199* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G199* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G199* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G199* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G199* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G199* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G199* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G199* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G199* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G199* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G199* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G199* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G199* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G199* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G245V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G245V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G245V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G245V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G245V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G245V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G245V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G245V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G245V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G245V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G245V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G245V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NTRK1 R702C Different Alteration Crizotinib (ALK inhibitor) Responsive LUAD Case report
NTRK1 R702C Different Alteration Pan-TKR inhibitor Responsive CANCER Early trials
NTRK1 R702C Different Alteration Pan-TK inhibitor Responsive LUAD Pre-clinical
NTRK1 R702C Different Alteration Pan-TK inhibitor Responsive COREAD Case report
TP53 I254S Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 I254S Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 I254S Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 I254S Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 I254S Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 I254S Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 I254S Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I254S Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 I254S Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 I254S Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 I254S Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 I254S Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I254S Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 I254S Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 I254S Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
LRP1B R2240* Complete Match Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
LRP1B R2240* Different Alteration Liposomal Doxorubicin (Chemotherapy) Resistant OV Early trials
CDKN2A E88* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E88* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E88* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A E88* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A E88* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A E88* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A E88* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A E88* Different Alteration CDK4/6 inhibitor Responsive CM Case report
ERCC4 Q65* Complete Match Cisplatin (Chemotherapy) Responsive OV Pre-clinical
TP53 S241F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 S241F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 S241F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 S241F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 S241F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 S241F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 S241F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 S241F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 S241F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 S241F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 S241F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 S241F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 S241F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
STK11 splice_donor_variant Different Mutation Everolimus (MTOR inhibitor) Responsive PA Case report
STK11 splice_donor_variant Complete Match Phenformin (Anti-diabetic) Responsive LUAD Pre-clinical
STK11 splice_donor_variant Complete Match MTOR inhibitor Responsive CANCER Pre-clinical
STK11 splice_donor_variant Complete Match BET inhibitor Resistant L Pre-clinical
STK11 splice_donor_variant Complete Match PD1 inhibitor Resistant CANCER Early trials
STK11 splice_donor_variant Complete Match SRC inhibitor;PI3K/MEK inhibitor Responsive LUAD Pre-clinical
STK11 splice_donor_variant Complete Match MEK inhibitor Responsive LUAD Pre-clinical
STK11 splice_donor_variant Different Alteration MTOR inhibitor Responsive CANCER Pre-clinical
STK11 splice_donor_variant Different Alteration PD1 inhibitor Resistant CANCER Early trials
STK11 splice_donor_variant Different Alteration Phenformin (Anti-diabetic) Responsive LUAD Pre-clinical
STK11 splice_donor_variant Different Alteration MEK inhibitor Responsive LUAD Pre-clinical
STK11 splice_donor_variant Different Alteration SRC inhibitor;PI3K/MEK inhibitor Responsive LUAD Pre-clinical
STK11 splice_donor_variant), KRAS MUT (G12D Complete Match MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) Resistant LUAD Pre-clinical
STK11 splice_donor_variant), KRAS MUT (G12D Complete Match PD1 Ab inhibitor Resistant LUAD Early trials
STK11 splice_donor_variant), KRAS MUT (G12D Different Alteration PD1 Ab inhibitor Resistant LUAD Early trials
STK11 splice_donor_variant), KRAS MUT (G12D Different Alteration MEK inhibitor;Docetaxel (MEK inhibitor;Chemotherapy) Resistant LUAD Pre-clinical
SF3B1 G740E Different Mutation Spliceosome inhibitor Responsive CANCER Pre-clinical
TP53 P250L Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 P250L Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 P250L Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 P250L Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 P250L Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 P250L Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 P250L Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P250L Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 P250L Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 P250L Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 P250L Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 P250L Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P250L Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 P250L Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 P250L Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R337C Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R337C Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R337C Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R337C Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R337C Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R337C Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R337C Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R337C Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R337C Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R337C Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R337C Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R337C Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R337C Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R337C Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R337C Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
CTNNB1 T41A Different Mutation Everolimus;Letrozole (MTOR inhibitor;Hormonal therapy) Responsive ED Early trials
CTNNB1 T41A Complete Match Tankyrase inhibitor Resistant COREAD Pre-clinical
NTRK3 intron_variant Different Alteration IGF1R inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration PI3K pathway inhibitor Responsive BRCA Pre-clinical
NTRK3 intron_variant Different Alteration Midostaurin (Pan-TK inhibitor) Responsive BRCA Pre-clinical
TP53 V274F Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 V274F Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 V274F Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 V274F Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 V274F Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 V274F Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 V274F Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V274F Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 V274F Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 V274F Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 V274F Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 V274F Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V274F Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 V274F Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 V274F Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R306* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 R306* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 R306* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 R306* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 R306* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 R306* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 R306* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R306* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 R306* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 R306* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 R306* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 R306* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R306* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 R306* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 R306* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
NOTCH1 C449C Different Alteration Gamma secretase inhibitor Responsive ALL Pre-clinical
NOTCH1 C449C Different Alteration Gamma secretase inhibitor Responsive BRCA Pre-clinical
TP53 L194H Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 L194H Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 L194H Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 L194H Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 L194H Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 L194H Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 L194H Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L194H Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 L194H Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 L194H Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 L194H Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 L194H Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L194H Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 L194H Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 L194H Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
PIK3CA M1043L Different Mutation BRAF inhibitor Resistant CM Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive BLCA, HNC Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive HNSC Case report
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive G, THCA Pre-clinical
PIK3CA M1043L Complete Match Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) Responsive BRCA Late trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive COREAD Pre-clinical
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive ED, OV, CESC Early trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive BRCA Late trials
PIK3CA M1043L Complete Match PIK3CA inhibitor Responsive BRCA Early trials
PIK3CA M1043L Complete Match PIK3CA inhibitor Responsive ST Case report
PIK3CA M1043L Complete Match AKT inhibitor Responsive BRCA Early trials
PIK3CA M1043L Complete Match PI3K pathway inhibitor Responsive;Responsive L Pre-clinical;Case report
PIK3CA M1043L Complete Match Cetuximab (EGFR mAb inhibitor) Resistant COREAD Late trials
PIK3CA M1043L Different Alteration PI3K pathway inhibitor Resistant BRCA Pre-clinical
TP53 E286* Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 E286* Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 E286* Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 E286* Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 E286* Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 E286* Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 E286* Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E286* Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 E286* Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 E286* Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 E286* Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 E286* Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E286* Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 E286* Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 E286* Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM L1347* Different Mutation AZD6738 (ATR inhibitor) Responsive BCL Early trials
ATM L1347* Complete Match Cisplatin (Chemotherapy) Responsive BLCA Early trials
ATM L1347* Complete Match Olaparib (PARP inhibitor) Responsive ST, PRAD Early trials
ATM L1347* Complete Match PARP inhibitor Responsive ST Early trials
ATM L1347* Complete Match ATR inhibitor Responsive COREAD Case report
ATM L1347* Complete Match DNA-PKc inhibitor Responsive LY Pre-clinical
ATM L1347* Complete Match Temozolomide (Chemotherapy) Responsive G Pre-clinical
ATM L1347* Complete Match PD1/PDL1 inhibitor Responsive UTH Early trials
ATM L1347* Different Alteration PD1/PDL1 inhibitor Responsive UTH Early trials
ATM L1347* Different Alteration DNA-PKc inhibitor Responsive LY Pre-clinical
ATM L1347* Different Alteration PARP inhibitor Responsive ST Early trials
ATM L1347* Different Alteration ATR inhibitor Responsive COREAD Case report
ATM L1347* Different Alteration Cisplatin (Chemotherapy) Responsive BLCA Early trials
PLCG2 K539* Different Mutation Ibrutinib (BTK inhibitor) Resistant CLL Early trials
KMT2A R442Q Different Alteration EPZ-5676 (DOT1L inhibitor) Responsive ALL, MDS, AML Early trials
KMT2A R442Q Different Alteration BET inhibitor Responsive ALL Pre-clinical
KMT2A R442Q Different Alteration BET inhibitor Responsive AML Pre-clinical
KMT2A R442Q Different Alteration Daunorubicin (Chemotherapy) Responsive AML FDA guidelines
KMT2A R442Q Different Alteration Belinostat (HDAC inhibitor) Responsive AML Early trials
KMT2A R442Q Different Alteration DOT1L inhibitor Responsive AML Early trials
CDKN2A Q50* Complete Match Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A Q50* Complete Match CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A Q50* Complete Match CDK4/6 inhibitor Responsive CM Case report
CDKN2A Q50* Complete Match PD1 inhibitor Resistant CM Early trials
CDKN2A Q50* Different Alteration CDK4/6 inhibitor Responsive CANCER, G Pre-clinical
CDKN2A Q50* Different Alteration Ilorasertib (AURKA-VEGF inhibitor) Responsive CANCER Early trials
CDKN2A Q50* Different Alteration PD1 inhibitor Resistant CM Early trials
CDKN2A Q50* Different Alteration CDK4/6 inhibitor Responsive CM Case report
TP53 G154V Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 G154V Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 G154V Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 G154V Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 G154V Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 G154V Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 G154V Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G154V Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 G154V Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 G154V Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 G154V Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 G154V Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G154V Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 G154V Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 G154V Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
ARID1A Q1277* Complete Match EZH2 inhibitor Responsive OV Pre-clinical
ARID1A Q1277* Complete Match PD1 inhibitor Responsive OV Pre-clinical
ARID1A Q1277* Complete Match PARP inhibitor Responsive CANCER Pre-clinical
ARID1A Q1277* Complete Match ATR inhibitor Responsive CANCER Pre-clinical
PBRM1 splice_donor_variant Different Alteration Everolimus (MTOR inhibitor) Responsive R Pre-clinical
PBRM1 splice_donor_variant Complete Match anti-PD1 inhibitor Responsive RCCC Early trials
PBRM1 splice_donor_variant Complete Match Everolimus (MTOR inhibitor) Responsive RCC Early trials
PBRM1 splice_donor_variant Complete Match EZH2 inhibitor Responsive CANCER Pre-clinical
PBRM1 splice_donor_variant Different Alteration EZH2 inhibitor Responsive CANCER Pre-clinical
TP53 N239D Different Mutation HSP90 inhibitor Responsive CANCER Pre-clinical
TP53 N239D Complete Match Decitabine (Chemotherapy) Responsive AML, MDPS Early trials
TP53 N239D Complete Match Abemaciclib (CDK4/6 inhibitor) Resistant BRCA Early trials
TP53 N239D Different Mutation HDM2 inhibitor Responsive AML Early trials
TP53 N239D Complete Match Cisplatin (Chemotherapy) Resistant FGCT, MGCT Early trials
TP53 N239D Complete Match AZD6738 (ATR inhibitor) Responsive BCL Early trials
TP53 N239D Complete Match Gemcitabine (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N239D Complete Match Mitomycin C (Chemotherapy) Responsive BLCA Pre-clinical
TP53 N239D Complete Match WEE1 inhibitor Responsive HNC Pre-clinical
TP53 N239D Complete Match MDM2 inhibitor Resistant LIP Early trials
TP53 N239D Complete Match Doxorubicin (Anthracycline antitumor antibiotic) Responsive BLCA Pre-clinical
TP53 N239D Complete Match Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N239D Complete Match WEE1 inhibitor Responsive OV Early trials
TP53 N239D Different Alteration Pramlintide (Amylin analogue) Responsive THYM Pre-clinical
TP53 N239D Different Alteration AZD6738 (ATR inhibitor) Responsive BCL Early trials
Variation Gene Transcript Protein Alteration Consequence Tumour Driver Oncogenic Classification
Drug-Gene Interactions help

Druggable categories in the cohort

Focus the search to a gene of interest:

Loading...
Gene Interaction Source Interaction Types Drug Claim Primary Name Drug Name ChEMBL ID
KRAS CKB lenalidomide LENALIDOMIDE CHEMBL848
KRAS CKB GA201 IMGATUZUMAB CHEMBL2109389
KRAS CKB 3144
KRAS OncoKB Selumetinib SELUMETINIB CHEMBL1614701
KRAS CKB BKM120 BUPARLISIB CHEMBL2017974
KRAS CKB Gefitinib GEFITINIB CHEMBL939
KRAS CKB CGM097
KRAS CKB IRX4204 IRX-4204 CHEMBL75133
KRAS CKB MK2206 MK-2206 CHEMBL1079175
KRAS CKB Radiotherapy
KRAS CGI Sorafenib SORAFENIB CHEMBL1336
KRAS CIViC SCH772984
KRAS CIViC CISPLATIN
KRAS CIViC ERLOTINIB ERLOTINIB CHEMBL553
KRAS CIViC CHEMOTHERAPY
KRAS CKB APS-2-79
KRAS CKB GDC0879 CHEMBL525191 CHEMBL525191
KRAS CKB KO-947
KRAS CIViC AZD8186 AZD-8186 CHEMBL3545424
KRAS CKB Vemurafenib VEMURAFENIB CHEMBL1229517
KRAS CIViC PEMBROLIZUMAB PEMBROLIZUMAB CHEMBL3137343
KRAS CKB Ipatasertib IPATASERTIB CHEMBL2177390
KRAS OncoKB Cabozantinib CABOZANTINIB CHEMBL2105717
KRAS CKB Trametinib TRAMETINIB CHEMBL2103875
KRAS CKB GI-4000
KRAS ClearityFoundationBiomarkers PANITUMUMAB PANITUMUMAB CHEMBL1201827
KRAS CKB AZD5363 AZD-5363 CHEMBL2178577
KRAS CKB LY3009120 LY-3009120 CHEMBL3545195
KRAS CGI Lapatinib LAPATINIB CHEMBL554
KRAS ClearityFoundationBiomarkers RAFAMETINIB
KRAS OncoKB KO-947
KRAS DoCM CETUXIMAB CETUXIMAB CHEMBL1201577
KRAS CKB GDC-0068 IPATASERTIB CHEMBL2177390
KRAS CKB Cetuximab CETUXIMAB CHEMBL1201577
KRAS CKB DEL-22379
KRAS CGI Cetuximab CETUXIMAB CHEMBL1201577
KRAS CKB NS1
KRAS CGI BCL2 inhibitor
KRAS CIViC GDC-0623
KRAS DoCM PANITUMUMAB PANITUMUMAB CHEMBL1201827
KRAS CKB Selumetinib SELUMETINIB CHEMBL1614701
KRAS CKB AZD4785
KRAS CKB PKI-402 CHEMBL589258 CHEMBL589258
KRAS CIViC R1507 TEPROTUMUMAB CHEMBL1743079
KRAS OncoKB Trametinib TRAMETINIB CHEMBL2103875
KRAS CIViC DOCETAXEL DOCETAXEL CHEMBL92
KRAS CGI MEK inhibitor
KRAS CKB SAR245409 VOXTALISIB CHEMBL3545366
KRAS CKB Romidepsin ROMIDEPSIN CHEMBL1213490
KRAS CKB FOLFOX
KRAS CKB AUY922 NVP-AUY922 CHEMBL252164
KRAS CKB BGJ398 INFIGRATINIB CHEMBL1852688
KRAS CKB ARS-853
KRAS CKB Panitumumab PANITUMUMAB CHEMBL1201827
KRAS CIViC BEZ235 DACTOLISIB CHEMBL1879463
KRAS CKB VX-11e
KRAS ClearityFoundationBiomarkers TRAMETINIB TRAMETINIB CHEMBL2103875
KRAS CKB UC-857993
KRAS CIViC BEZ235 (NVP-BEZ235, DACTOLISIB) DACTOLISIB CHEMBL1879463
KRAS CGI Regorafenib REGORAFENIB CHEMBL1946170
KRAS CIViC GEMCITABINE GEMCITABINE CHEMBL888
KRAS CKB Reolysin
KRAS CIViC CETUXIMAB CETUXIMAB CHEMBL1201577
KRAS CKB Saracatinib SARACATINIB CHEMBL217092
KRAS CIViC PD0325901 PD-0325901 CHEMBL507361
KRAS CKB Dinaciclib DINACICLIB CHEMBL2103840
KRAS OncoKB Binimetinib BINIMETINIB CHEMBL3187723
KRAS CKB AMG 232
KRAS MyCancerGenomeClinicalTrial inhibitor REGORAFENIB REGORAFENIB CHEMBL1946170
KRAS CKB Osimertinib OSIMERTINIB CHEMBL3353410
KRAS CKB bortezomib BORTEZOMIB CHEMBL325041
KRAS OncoKB LY3214996
KRAS CIViC ADOPTIVE T-CELL TRANSFER
KRAS CKB Afatinib AFATINIB CHEMBL1173655
KRAS CKB Capecitabine CAPECITABINE CHEMBL1773
KRAS CKB DHM25
KRAS CKB PI-3065
KRAS TALC vaccine RAS PEPTIDE CANCER VACCINE
KRAS OncoKB Abemaciclib ABEMACICLIB CHEMBL3301610
KRAS CKB Sunitinib SUNITINIB CHEMBL535
KRAS CKB AT-7867 CHEMBL428462 CHEMBL428462
KRAS CKB Abemaciclib ABEMACICLIB CHEMBL3301610
KRAS CKB Olaparib OLAPARIB CHEMBL521686
KRAS CKB Ponatinib PONATINIB CHEMBL1171837
KRAS CIViC AZD5438 AZD-5438 CHEMBL488436
KRAS CIViC BEVACIZUMAB BEVACIZUMAB CHEMBL1201583
KRAS CKB GDC-0980 APITOLISIB CHEMBL1922094
KRAS CKB Alpelisib ALPELISIB CHEMBL2396661
KRAS CKB Copanlisib COPANLISIB CHEMBL3218576
KRAS CKB Venetoclax VENETOCLAX CHEMBL3137309
KRAS CKB Pemetrexed PEMETREXED (CHEMBL1201258) CHEMBL1201258
KRAS CKB AZ-TAK1
KRAS CIViC PACLITAXEL PACLITAXEL CHEMBL428647
KRAS CKB MLN2480 MLN-2480 CHEMBL3348923
KRAS CKB AZD4547 AZD-4547 CHEMBL3184679
KRAS CKB AMG 337 AMG-337 CHEMBL3545212
KRAS ClearityFoundationBiomarkers TEMSIROLIMUS TEMSIROLIMUS CHEMBL1201182
KRAS OncoKB Atezolizumab ATEZOLIZUMAB CHEMBL3707227
KRAS CKB Panobinostat PANOBINOSTAT CHEMBL483254
KRAS OncoKB Docetaxel DOCETAXEL CHEMBL92
KRAS CKB LY411575 CHEMBL392068 CHEMBL392068
KRAS CKB Necitumumab NECITUMUMAB CHEMBL1743047
KRAS CKB Phenformin PHENFORMIN CHEMBL170988
KRAS CGI Trametinib TRAMETINIB CHEMBL2103875
KRAS CKB Oxaliplatin OXALIPLATIN CHEMBL414804
KRAS CKB Vistusertib BENZONATATE CHEMBL1374379
KRAS CKB LY294002 LY-294002 CHEMBL98350
KRAS CKB 7RH
KRAS ClearityFoundationBiomarkers EVEROLIMUS EVEROLIMUS CHEMBL1908360
KRAS CKB PD98509
KRAS CKB Trastuzumab TRASTUZUMAB CHEMBL1201585
KRAS CKB AZD9291 OSIMERTINIB CHEMBL3353410
KRAS CKB Neratinib NERATINIB CHEMBL180022
KRAS CKB Ridaforolimus RIDAFOROLIMUS CHEMBL2103839
KRAS CKB A-443654 A-443654 CHEMBL379300
KRAS CKB UC-773587
KRAS CKB Gemcitabine GEMCITABINE CHEMBL888
KRAS CKB SAR125844 SAR-125844 CHEMBL3545325
KRAS CKB Navitoclax NAVITOCLAX CHEMBL443684
KRAS CKB DT-061
KRAS CKB GSK343
KRAS CKB GDC-0032 TASELISIB CHEMBL2387080
KRAS CKB Binimetinib BINIMETINIB CHEMBL3187723
KRAS CIViC GEFITINIB GEFITINIB CHEMBL939
KRAS CKB KRAS mutant-specific TIL
KRAS CGI MEK
KRAS CKB DZNep
KRAS CKB AT13148 AT-13148 CHEMBL3544960
KRAS CKB Aurora Kinase Inhibitor II ANILINOQUINAZOLINE1 CHEMBL382590
KRAS CIViC DECITABINE DECITABINE CHEMBL1201129
KRAS CKB Ixabepilone IXABEPILONE CHEMBL1201752
KRAS CKB AZD8835 CANDICIDIN CHEMBL1200647
KRAS CGI Selumetinib SELUMETINIB CHEMBL1614701
KRAS CIViC PEMETREXED PEMETREXED (CHEMBL1201258) CHEMBL1201258
KRAS CKB Ralimetinib RALIMETINIB CHEMBL2364626
KRAS CKB Pimasertib PIMASERTIB CHEMBL2107832
KRAS CKB AG490 CHEMBL56543 CHEMBL56543
KRAS CKB Carboplatin CARBOPLATIN CHEMBL1351
KRAS CKB CI-1040 CI-1040 CHEMBL105442
KRAS CKB PF3644022 CHEMBL1231206 CHEMBL1231206
KRAS CKB Paclitaxel PACLITAXEL CHEMBL428647
KRAS CKB AZD8186 AZD-8186 CHEMBL3545424
KRAS CIViC NIVOLUMAB NIVOLUMAB CHEMBL2108738
KRAS CKB Salirasib SALIRASIB CHEMBL23293
KRAS CKB Atezolizumab ATEZOLIZUMAB CHEMBL3707227
KRAS CIViC ABEMACICLIB ABEMACICLIB CHEMBL3301610
KRAS CKB BI2536 BI-2536 CHEMBL513909
KRAS GuideToPharmacologyInteractions inhibitor LONAFARNIB LONAFARNIB CHEMBL298734
KRAS CKB CC-223 CC-223 CHEMBL3545151
KRAS CKB SCH772984
KRAS CKB Pazopanib PAZOPANIB CHEMBL477772
KRAS CKB PF-04691502 PF-04691502 CHEMBL1234354
KRAS CKB Cobimetinib COBIMETINIB CHEMBL2146883
KRAS CKB CID1067700
KRAS CGI Panitumumab PANITUMUMAB CHEMBL1201827
KRAS CIViC FOLFOX4
KRAS CKB rigosertib RIGOSERTIB CHEMBL1241855
KRAS OncoKB Regorafenib REGORAFENIB CHEMBL1946170
KRAS CKB AZD8055 AZD-8055 CHEMBL1801204
KRAS CGI Ponatinib PONATINIB CHEMBL1171837
KRAS CKB Rilotumumab RILOTUMUMAB CHEMBL1743063
KRAS OncoKB Cobimetinib COBIMETINIB CHEMBL2146883
KRAS CKB Midostaurin MIDOSTAURIN CHEMBL608533
KRAS CKB GDC-0941 PICTILISIB CHEMBL521851
KRAS CIViC G-573
KRAS CKB Lapatinib LAPATINIB CHEMBL554
KRAS CKB BEZ235 DACTOLISIB CHEMBL1879463
KRAS CKB cabozantinib CABOZANTINIB CHEMBL2105717
KRAS CKB Cisplatin
KRAS CKB PHT-427
KRAS CGI BCL2
KRAS CKB KPT-185
KRAS CIViC TRAMETINIB TRAMETINIB CHEMBL2103875
KRAS OncoKB GDC-0994 GDC-0994 CHEMBL3544964
KRAS ClearityFoundationBiomarkers GEFITINIB GEFITINIB CHEMBL939
KRAS CKB OSI-027 OSI-027 CHEMBL3120215
KRAS OncoKB Palbociclib PALBOCICLIB CHEMBL189963
KRAS CKB cobimetinib COBIMETINIB CHEMBL2146883
KRAS MyCancerGenomeClinicalTrial inhibitor SELUMETINIB SELUMETINIB CHEMBL1614701
KRAS ClearityFoundationBiomarkers PD-325901 PD-0325901 CHEMBL507361
KRAS OncoKB Panitumumab PANITUMUMAB CHEMBL1201827
KRAS OncoKB Ribociclib Ribociclib CHEMBL3545110
KRAS CKB PF-477736 PF-00477736 CHEMBL3545137
KRAS CIViC EGFR INHIBITOR CHEMBL387187 CHEMBL387187
KRAS CKB Demcizumab DEMCIZUMAB CHEMBL2109384
KRAS CKB Volasertib VOLASERTIB CHEMBL1233528
KRAS CKB Pembrolizumab PEMBROLIZUMAB CHEMBL3137343
KRAS CGI inhibitor
KRAS CKB SH-1242
KRAS CKB DS-7423 DS-7423 CHEMBL3545248
KRAS CKB BGB-283 BGB-283 CHEMBL3545246
KRAS CKB AZ628
KRAS CKB SHP099
KRAS CKB GDC-0623
KRAS CKB
KRAS CKB Sirolimus SIROLIMUS CHEMBL413
KRAS CKB Erlotinib ERLOTINIB CHEMBL553
KRAS CKB BAY1082439 BAY-1082439 CHEMBL3545245
KRAS CIViC ATEZOLIZUMAB ATEZOLIZUMAB CHEMBL3707227
KRAS CKB Tazemetostat
KRAS CIViC BINIMETINIB BINIMETINIB CHEMBL3187723
KRAS CKB JNJ-42756493 JNJ-42756493 CHEMBL3545376
KRAS CKB Regorafenib REGORAFENIB CHEMBL1946170
KRAS CKB BYL719 ALPELISIB CHEMBL2396661
KRAS CKB Refametinib Refametinib CHEMBL2138601
KRAS CKB RO5126766
KRAS CKB PX-866 SONOLISIB CHEMBL411907
KRAS CKB TAE226 CHEMBL458997 CHEMBL458997
KRAS CKB Nilotinib NILOTINIB CHEMBL255863
KRAS CKB Palbociclib PALBOCICLIB CHEMBL189963
KRAS CKB Camptothecin CAMPTOTHECIN CHEMBL65
KRAS CKB P7170 Panulisib CHEMBL3545322
KRAS CKB Sapanisertib INK-128 CHEMBL3545056
KRAS CKB XL147 PILARALISIB (CHEMBL3218575) CHEMBL3218575
KRAS CKB Metformin METFORMIN CHEMBL1431
KRAS CKB MLN0128 INK-128 CHEMBL3545056
KRAS OncoKB Erlotinib ERLOTINIB CHEMBL553
KRAS CKB Docetaxel DOCETAXEL CHEMBL92
KRAS ClearityFoundationBiomarkers MEK162 BINIMETINIB CHEMBL3187723
KRAS CIViC RAF265 CHIR-265 CHEMBL558752
KRAS CKB RO4987655 Ro-4987655 CHEMBL1614766
KRAS CKB TVB-2640
KRAS CKB Encorafenib ENCORAFENIB CHEMBL3301612
KRAS CKB Danusertib DANUSERTIB CHEMBL402548
KRAS CKB MLN1117 INK-1117 CHEMBL3545055
KRAS CKB Linsitinib LINSITINIB CHEMBL1091644
KRAS CIViC DASATINIB DASATINIB CHEMBL1421
KRAS CKB BAY1125976 BAY-1125976 CHEMBL3545049
KRAS CKB TW-37 CHEMBL217354 CHEMBL217354
KRAS CKB ABT-737 CHEMBL376408 CHEMBL376408
KRAS MyCancerGenomeClinicalTrial inhibitor SIMVASTIN
KRAS TdgClinicalTrial GI-4000
KRAS ClearityFoundationBiomarkers VANDETANIB VANDETANIB CHEMBL24828
KRAS CKB Fluorouracil FLUOROURACIL CHEMBL185
KRAS CKB BBI608 2-ACETYL FURANONAPTHOQUINONE CHEMBL64130
KRAS CKB BVD-523 Ulixertinib CHEMBL3545022
KRAS CKB Rigosertib RIGOSERTIB CHEMBL1241855
KRAS CKB LGX818 ENCORAFENIB CHEMBL3301612
KRAS ClearityFoundationBiomarkers GDC-0973 COBIMETINIB CHEMBL2146883
KRAS CIViC SELUMETINIB (AZD6244) SELUMETINIB CHEMBL1614701
KRAS CKB OPB-111077
KRAS CKB Dasatinib DASATINIB CHEMBL1421
KRAS CKB WEHI-539
KRAS CIViC PANITUMUMAB PANITUMUMAB CHEMBL1201827
KRAS CKB Doxil
KRAS CIViC AFATINIB AFATINIB CHEMBL1173655
KRAS CKB BI-847325
KRAS CIViC CARBOPLATIN CARBOPLATIN CHEMBL1351
KRAS ClearityFoundationBiomarkers CETUXIMAB CETUXIMAB CHEMBL1201577
KRAS CKB PD-0325901 PD-0325901 CHEMBL507361
KRAS CGI Decitabine DECITABINE CHEMBL1201129
KRAS CKB BMS-754807 BMS-754807 CHEMBL575448
KRAS CKB Deguelin DEGUELIN CHEMBL393417
KRAS CKB PF-05212384 GEDATOLISIB CHEMBL592445
KRAS CKB fasudil FASUDIL CHEMBL38380
KRAS CKB poziotinib Poziotinib CHEMBL3545154
KRAS CKB VX-970 VX-970 CHEMBL3545202
KRAS CGI Imatinib IMATINIB CHEMBL941
KRAS CKB Everolimus EVEROLIMUS CHEMBL1908360
KRAS CancerCommons inhibitor REOLYSIN
KRAS CKB CUDC-907 CUDC-907 CHEMBL3545052
KRAS ClearityFoundationBiomarkers ERLOTINIB ERLOTINIB CHEMBL553
KRAS CKB MK-1775 AZD-1775 CHEMBL1976040
KRAS CKB Aphanin
KRAS ClearityFoundationBiomarkers PIMASERTIB PIMASERTIB CHEMBL2107832
KRAS ClearityFoundationBiomarkers SELUMETINIB SELUMETINIB CHEMBL1614701
KRAS CKB Irinotecan IRINOTECAN CHEMBL481
KRAS CGI Trastuzumab TRASTUZUMAB CHEMBL1201585
KRAS CIViC ARRY-142886 SELUMETINIB CHEMBL1614701
KRAS CKB Ramucirumab RAMUCIRUMAB CHEMBL1743062
KRAS CKB SML-10-70-1
KRAS CKB MEK162 BINIMETINIB CHEMBL3187723
KRAS CKB FOLFIRI CETUXIMAB CHEMBL1201577
KRAS CIViC ARS-853
KRAS CKB ER2
KRAS CKB Temsirolimus TEMSIROLIMUS CHEMBL1201182
KRAS CKB Sorafenib SORAFENIB CHEMBL1336
KRAS CGI Docetaxel DOCETAXEL CHEMBL92
KRAS OncoKB Cetuximab CETUXIMAB CHEMBL1201577
KRAS CGI Palbociclib PALBOCICLIB CHEMBL189963
KRAS CIViC ENCORAFENIB ENCORAFENIB CHEMBL3301612
KRAS CKB Crizotinib CRIZOTINIB CHEMBL601719
KRAS CKB Dabrafenib DABRAFENIB CHEMBL2028663
KRAS CKB GSK1120212 TRAMETINIB CHEMBL2103875
KRAS CIViC PALBOCICLIB PALBOCICLIB CHEMBL189963
KRAS CGI Abemaciclib ABEMACICLIB CHEMBL3301610
KRAS CKB SRA737
KRAS CKB Bevacizumab BEVACIZUMAB CHEMBL1201583
KRAS CKB CC-90003
KRAS CKB TAK-733 TAK-733 CHEMBL1615025
KRAS CKB Gedatolisib GEDATOLISIB CHEMBL592445
KRAS CKB XMT-1536
KRAS CGI Gemcitabine GEMCITABINE CHEMBL888
KRAS CKB ABT-263 NAVITOCLAX CHEMBL443684
KRAS CKB CH5132799 PA-799 CHEMBL1684984
Interactions & Pathways
Oncogenic Pathways help
Loading...
Interaction Networks help
Legend:
  • Phenotype
  • Protein
  • Drug
Loading...

Select a gene to see its drug/phenotype/protein interactions

Reactome Pathways help

All significant pathways (p<0.05) in the selected cohort are presented in the Voronoi interactive plot, with colour intensity representing the number of patients affected
Click here to show visualisation below or here to open the visualisation in a new window

Principal Component Analysis
PCA Help

Scatterplot of Two main Principal Components

Click on legend to highlight trace

Scatterplot of Three main Principal Components

Gene Expression
Loading...
Gene Expression Help

Box Plot

Bar Plot

Correlation
Correlation Help
Loading...
Survival Analysis
Survival Analysis Help
Loading...

There are Blood (Plasma, Serum, Buffy coat), FFPE tissue, Fresh frozen tissue samples from unique donors available at PCRFTB, based on the selected clinical filters (Age, Sex, Race, Diagnosis). Researchers can request for samples by submitting an Expression of Interest to PCRFTB.

Overview
Sex
Race
Diagnosis
Tumor stage
Age at Diagnosis